BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. N Engl J Med 2001;345:725-30. [DOI: 10.1056/nejmoa010187] [Cited by in Crossref: 2301] [Cited by in F6Publishing: 910] [Article Influence: 109.6] [Reference Citation Analysis]
Number Citing Articles
1 Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605-18. [PMID: 29950898 DOI: 10.2147/CMAR.S151552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yan H, Chen Y, Yang Z, Li Z, Che X, Xiao J, Liu Y, Qu X. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer. Front Immunol 2020;11:621623. [PMID: 33613554 DOI: 10.3389/fimmu.2020.621623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ruiz-Tovar J, Lacueva FJ, Oliver I, Martínez A, Calpena R. [Complication of postoperative chemoradiation in a patient with gastric cancer]. Cir Esp 2011;89:554-5. [PMID: 21342685 DOI: 10.1016/j.ciresp.2010.06.023] [Reference Citation Analysis]
4 Dikken JL, Verheij M, Cats A, Jansen EP, Hartgrink HH, van de Velde CJ. Extended lymph node dissection for gastric cancer from a European perspective. Gastric Cancer. 2011;14:396-398. [PMID: 21837457 DOI: 10.1007/s10120-011-0081-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
5 Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker AP. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst 2013;105:11-24. [PMID: 23231975 DOI: 10.1093/jnci/djs472] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
6 Kim Y, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Lee SJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. J Gastric Cancer 2018;18:348-55. [PMID: 30607298 DOI: 10.5230/jgc.2018.18.e34] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Katona BW, Rustgi AK. Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol. 2017;3:211-217. [PMID: 28275688 DOI: 10.1016/j.jcmgh.2017.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
8 Choi YY, An JY, Hyung WJ, Noh SH. Comments to young surgeons concerning laparoscopic spleen-preserving D2 lymph node dissection for advanced gastric cancer on the upper body. Chin J Cancer Res 2014;26:231-3. [PMID: 25035646 DOI: 10.3978/j.issn.1000-9604.2014.06.15] [Reference Citation Analysis]
9 Brenkman HJ, Haverkamp L, Ruurda JP, van Hillegersberg R. Worldwide practice in gastric cancer surgery. World J Gastroenterol 2016; 22(15): 4041-4048 [PMID: 27099448 DOI: 10.3748/wjg.v22.i15.4041] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
10 Li YF, Wang DD, Zhao BW, Wang W, Yuan SQ, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC, Zhou ZW. Poor prognosis of gastric adenocarcinoma with decreased expression of AHRR. PLoS One 2012;7:e43555. [PMID: 22952704 DOI: 10.1371/journal.pone.0043555] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
11 Wang Q, Liu X, Zhou J, Huang Y, Zhang S, Shen J, Loera S, Yuan X, Chen W, Jin M, Shibata S, Liu Y, Chu P, Wang L, Yen Y. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PLoS One 2013;8:e70191. [PMID: 23922955 DOI: 10.1371/journal.pone.0070191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
12 Créhange G, Modesto A, Vendrely V, Quéro L, Mirabel X, Rétif P, Huguet F. Radiotherapy for cancers of the oesophagus, cardia and stomach. Cancer Radiother 2021:S1278-3218(21)00312-7. [PMID: 34955417 DOI: 10.1016/j.canrad.2021.11.022] [Reference Citation Analysis]
13 Miccio JA, Oladeru OT, Yang J, Xue Y, Choi M, Zhang Y, Yoon H, Ryu S, Stessin AM. Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. J Gastrointest Oncol 2016;7:403-10. [PMID: 27284473 DOI: 10.21037/jgo.2015.10.06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
14 Taguchi T, Bishop J. Challenge and opportunities in the treatment of gastric cancer. Gastric Cancer 2002;5 Suppl 1:1-3. [PMID: 12772879 DOI: 10.1007/s10120-002-0206-3] [Reference Citation Analysis]
15 Garofalo MC, Kwok Y, Regine WF. The evolving role of postoperative adjuvant radiation therapy for pancreatic cancer. Surg Oncol Clin N Am 2004;13:589-604, viii. [PMID: 15350936 DOI: 10.1016/j.soc.2004.06.012] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Pruthi DS, Ahmad M, Gupta M, Bansal S, Nautiyal V, Saini S. Assessment of quality of life in resectable gastric cancer patients undergoing chemoradiotherapy as adjuvant treatment. South Asian J Cancer 2018;7:16-20. [PMID: 29600226 DOI: 10.4103/sajc.sajc_196_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yusufu A, Tuerdi R, Redati D, Rehemutula A, Zhao ZL, Wang HJ. Expression and clinical correlation of Survivin and PTEN in gastric cancer patients. Oncol Lett 2020;20:297. [PMID: 33101491 DOI: 10.3892/ol.2020.12160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503. [DOI: 10.1038/nrclinonc.2011.45] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
19 Schmidt B, Yoon SS. Varying lymphadenectomies for gastric adenocarcinoma in the East compared with the west: effect on outcomes. Am Soc Clin Oncol Educ Book 2012;:250-5. [PMID: 24451743 DOI: 10.14694/EdBook_AM.2012.32.28] [Reference Citation Analysis]
20 Cheng X, Zheng Z, Bu Z, Wu X, Zhang L, Xing X, Wang X, Hu Y, Du H, Li L. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients. PLoS One. 2015;10:e0121559. [PMID: 25849595 DOI: 10.1371/journal.pone.0121559] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
21 Squires MH 3rd, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA 3rd, Farris AB 3rd, Maithel SK. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer 2013;119:3242-50. [PMID: 23719746 DOI: 10.1002/cncr.28175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
22 Uyeturk U, Arslan SH, Bal O, Arslan UY, Oksuzoglu OB. Isolated ovarian metastasis of gastric cancer: Krukenberg tumor. Contemp Oncol (Pozn) 2013;17:515-9. [PMID: 24592139 DOI: 10.5114/wo.2013.37542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Yang W, Zhou M, Li G, Shen L, Wang Y, Zhang H, Wang Y, Zhang J, Sun X, Zhang Z, Zou W, Zhang Z. Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy for Patients With Locally Advanced Gastric Cancer: A Retrospective Study Based on Propensity Score Analyses. Front Oncol 2020;10:560115. [PMID: 33178589 DOI: 10.3389/fonc.2020.560115] [Reference Citation Analysis]
24 Hensel F, Timmermann W, von Rahden BH, Rosenwald A, Brändlein S, Illert B. Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep 2014;31:1059-66. [PMID: 24452482 DOI: 10.3892/or.2014.2987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
25 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 218] [Article Influence: 84.8] [Reference Citation Analysis]
26 Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG. Reply to Tumor localization may change the type of adjuvant treatment in gastric cancer. Cancer 2017;123:4737-8. [PMID: 28981979 DOI: 10.1002/cncr.31018] [Reference Citation Analysis]
27 Sun KK, Wang QH, Wu YY. Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer. Oncol Lett 2020;20:126. [PMID: 32934695 DOI: 10.3892/ol.2020.11985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Cohen RJ, Paskalev K, Litwin S, Price RA Jr, Feigenberg SJ, Konski AA. Esophageal motion during radiotherapy: quantification and margin implications. Dis Esophagus 2010;23:473-9. [PMID: 20095993 DOI: 10.1111/j.1442-2050.2009.01037.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
29 Enzinger PC, Benedetti JK, Meyerhardt JA, McCoy S, Hundahl SA, Macdonald JS, Fuchs CS. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007;245:426-434. [PMID: 17435550 DOI: 10.1097/01.sla.0000245469.35088.42] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
30 Elmi M, Mahar A, Kagedan D, Law CH, Karanicolas PJ, Lin Y, Callum J, Coburn NG, Hallet J. The impact of blood transfusion on perioperative outcomes following gastric cancer resection: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Can J Surg 2016;59:322-9. [PMID: 27668330 DOI: 10.1503/cjs.004016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
31 Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-. Radiat Oncol 2014;9:9. [PMID: 24398302 DOI: 10.1186/1748-717X-9-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
32 Ma HY, Liu XZ, Liang CM. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J Gastroenterol 2016; 22(29): 6619-6628 [PMID: 27547005 DOI: 10.3748/wjg.v22.i29.6619] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
33 Ozen A, Kocak Z, Sipahi T, Oz-Puyan F, Cakina S, Saynak M, Ibis C, Karagol H. The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol 2013;30:357. [PMID: 23275116 DOI: 10.1007/s12032-012-0357-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
34 Röcken C, Behrens HM, Böger C, Krüger S. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. J Clin Pathol 2016;69:70-5. [PMID: 26251521 DOI: 10.1136/jclinpath-2015-202980] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
35 Keshari RP, Wang W, Zhang Y, Wang DD, Li YF, Yuan SQ, Qiu HB, Huang CY, Chen YM, Xia JC, Zhou ZW. Decreased expression of the GATA3 gene is associated with poor prognosis in primary gastric adenocarcinoma. PLoS One 2014;9:e87195. [PMID: 24504018 DOI: 10.1371/journal.pone.0087195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
36 Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol. 2009;14:85-89. [PMID: 19390937 DOI: 10.1007/s10147-009-0877-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
37 Raman V, Jawitz OK, Voigt SL, Yang CJ, D'Amico TA, Harpole DH Jr. The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. J Surg Res 2020;249:82-90. [PMID: 31926400 DOI: 10.1016/j.jss.2019.11.035] [Reference Citation Analysis]
38 Levine EA, Shen P, Shiver SA, Waters G, Brant A, Geisenger KR. Intraoperative imprint cytology for evaluation of sentinel lymph nodes from visceral malignancies. J Gastrointest Surg 2003;7:687-91. [PMID: 12850683 DOI: 10.1016/s1091-255x(03)00069-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Agolli L, Maurizi Enrici R, Osti MF. Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients? World J Gastroenterol 2016; 22(3): 1131-1138 [PMID: 26811652 DOI: 10.3748/wjg.v22.i3.1131] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
40 Abuderman AA. Gastric cancer & prospects of cancer in Saudi Arabia peninsula. Saudi J Biol Sci 2019;26:1095-100. [PMID: 31516334 DOI: 10.1016/j.sjbs.2018.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
41 Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the Treatment of Gastric Cancer. JMA J 2018;1:40-9. [PMID: 33748521 DOI: 10.31662/jmaj.2018-0006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
42 Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 2021;123:911-22. [PMID: 33400838 DOI: 10.1002/jso.26367] [Reference Citation Analysis]
43 O'Leary BR, Houwen FK, Johnson CL, Allen BG, Mezhir JJ, Berg DJ, Cullen JJ, Spitz DR. Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma. Radiat Res 2018;189:456-65. [PMID: 29547353 DOI: 10.1667/RR14978.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
44 Matuschek C, Haussmann J, Bölke E, Tamaskovics B, Djiepmo Njanang FJ, Orth K, Peiper M, Gerber PA, Anooshar B, Kammers K, Budach W. Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis. Strahlenther Onkol 2019;195:695-706. [PMID: 30796495 DOI: 10.1007/s00066-019-01431-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
45 Ciesielski M, Szajewski M, Walczak J, Pęksa R, Lenckowski R, Supeł M, Zieliński J, Kruszewski WJ. Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma. Oncol Lett 2021;21:142. [PMID: 33552261 DOI: 10.3892/ol.2020.12403] [Reference Citation Analysis]
46 Barsky AR, Reddy VK, Plastaras JP, Ben-Josef E, Metz JM, Wojcieszynski AP. Proton beam re-irradiation for gastrointestinal malignancies: a systematic review. J Gastrointest Oncol 2020;11:187-202. [PMID: 32175122 DOI: 10.21037/jgo.2019.09.03] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Rhome RM, Ru M, Moshier E, Mazumdar M, Buckstein MH. Stage-matched survival differences by ethnicity among gastric cancer patients of Asian ancestry treated in the United States. J Surg Oncol 2019;119:737-48. [PMID: 30694524 DOI: 10.1002/jso.25389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Huang L, Feng B, Li Y, Liu Y, Chen Y, Chen Q, Li C, Huang W, Xue H, Li X, Zhou T, Li R, Long W, Feng ST. Computed Tomography-Based Radiomics Nomogram: Potential to Predict Local Recurrence of Gastric Cancer After Radical Resection. Front Oncol 2021;11:638362. [PMID: 34540653 DOI: 10.3389/fonc.2021.638362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Chen L, Zhang C, Yao Z, Cui M, Xing J, Yang H, Zhang N, Liu M, Xu K, Tan F, Li Y, Jiang B, Su X. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. BMC Cancer 2021;21:974. [PMID: 34461860 DOI: 10.1186/s12885-021-08717-4] [Reference Citation Analysis]
50 Ren F, Li S, Zhang Y, Zhao Z, Wang H, Cui Y, Wang M. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol 2019;14:84. [PMID: 31118042 DOI: 10.1186/s13014-019-1294-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
51 Meyer HJ, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke H, Möhler M. [Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg 2012;83:31-7. [PMID: 22127381 DOI: 10.1007/s00104-011-2149-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
52 Unek IT, Unek T, Oztop I, Akman T, Atilla K, Ellidokuz H, Bora S, Sarioglu S, Yilmaz U. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma. Chemotherapy 2012;58:233-40. [PMID: 22832016 DOI: 10.1159/000339493] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 . GASTROINTESTINAL CANCERS. Cancer Investigation 2009;25:9-16. [DOI: 10.1080/07357900701571726] [Reference Citation Analysis]
54 Spolverato G, Kim Y, Ejaz A, Valero V 3rd, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Acher AW, Votanopoulos K, Schmidt C, Cho CS, Maithel SK, Pawlik TM. A multi-institutional analysis of open versus minimally-invasive surgery for gastric adenocarcinoma: results of the US gastric cancer collaborative. J Gastrointest Surg 2014;18:1563-74. [PMID: 24912915 DOI: 10.1007/s11605-014-2562-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
55 Shiraishi K, Mimura K, Izawa S, Inoue A, Shiba S, Maruyama T, Watanabe M, Kawaguchi Y, Inoue M, Fujii H. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. 2013;16:571-580. [PMID: 23187882 DOI: 10.1007/s10120-012-0219-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
56 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
57 von Wichert G, Seufferlein T. [Adjuvant chemotherapy of solid tumors of the gastrointestinal tract: where is the progress?]. Internist (Berl) 2007;48:1335-42. [PMID: 17965842 DOI: 10.1007/s00108-007-1974-y] [Reference Citation Analysis]
58 Shen J, Zhu X, Du Y, Zhu Y, Yu P, Yang L, Xu Z, Huang L, Zhang Y, Zhang Y, Liu L, Cheng X. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials 2021;22:753. [PMID: 34717717 DOI: 10.1186/s13063-021-05617-7] [Reference Citation Analysis]
59 Barzi A, Yang D, Kim AW, Shah MA, Sadeghi S. Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterol 2020;7:e000483. [PMID: 33148789 DOI: 10.1136/bmjgast-2020-000483] [Reference Citation Analysis]
60 Tham CK, Choo SP, Poon DYH, Toh HC, Ong SYK, Tan SH, Wang MLC, Foo KF. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010; 16(29): 3709-3715 [PMID: 20677345 DOI: 10.3748/wjg.v16.i29.3709] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
61 Peixoto RD, Cheung WY, Lim HJ. Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol 2014;21:77-83. [PMID: 24764696 DOI: 10.3747/co.21.1788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A. Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012;5:49-69. [PMID: 22282708 DOI: 10.1177/1756283x11410771] [Cited by in Crossref: 48] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
63 Chen S, Feng X, Li Y, Yuan X, Zhou Z, Chen Y. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy. Oncol Lett 2012;3:781-6. [PMID: 22740993 DOI: 10.3892/ol.2012.577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
64 Wagner AD, Wedding U. Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging. 2009;26:627-646. [PMID: 19685930 DOI: 10.2165/11315740-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
65 Bargiela-Iparraguirre J, Prado-Marchal L, Fernandez-Fuente M, Gutierrez-González A, Moreno-Rubio J, Muñoz-Fernandez M, Sereno M, Sanchez-Prieto R, Perona R, Sanchez-Perez I. CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. Sci Rep 2016;6:21519. [PMID: 26867682 DOI: 10.1038/srep21519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
66 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-490. [PMID: 19625077 DOI: 10.1016/s0140-6736(09)60617-6] [Cited by in Crossref: 635] [Cited by in F6Publishing: 407] [Article Influence: 48.8] [Reference Citation Analysis]
67 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Park S, Woo Y, Kim H, Lee YC, Choi S, Hyung WJ, Noh SH. In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer. J Gastric Cancer 2010;10:155-61. [PMID: 22076180 DOI: 10.5230/jgc.2010.10.4.155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
69 Morgagni P, Tringali D, La Barba G, Vittimberga G, Ercolani G. Historical assumptions of lymphadenectomy. Transl Gastroenterol Hepatol 2016;1:90. [PMID: 28138655 DOI: 10.21037/tgh.2016.11.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69-78. [PMID: 19562460 DOI: 10.1007/s10120-009-0505-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
71 Natori A, Chan BA, Sim HW, Ma L, Yokom DW, Chen E, Liu G, Darling G, Swallow C, Brar S, Brierley J, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox J, Elimova E, Jang RW. Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer. Curr Oncol 2018;25:366-70. [PMID: 30607110 DOI: 10.3747/co.25.4208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Pectasides E, Chatzidakis I, Kotoula V, Koliou GA, Papadopoulou K, Giannoulatou E, Giannouzakos VG, Bobos M, Papavasileiou C, Chrisafi S, Florou A, Pectasides D, Fountzilas G. Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics Proteomics 2020;17:277-90. [PMID: 32345669 DOI: 10.21873/cgp.20188] [Reference Citation Analysis]
73 Lago NM, Villar MV, Ponte RV, Nallib IA, Alvarez JJC, López JRA, López RL, Iruegas MEP. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience 2020;14:1020. [PMID: 32256703 DOI: 10.3332/ecancer.2020.1020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Korourian A, Roudi R, Shariftabrizi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242:1842-1847. [PMID: 28836853 DOI: 10.1177/1535370217728460] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
75 Krasna MJ. Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'. Drugs Aging 2009;26:185-94. [PMID: 19358615 DOI: 10.2165/00002512-200926030-00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
76 Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Escrig Sos J, Martínez Ramos D. New technologies in cancer and their assessment. The clinical surgeon's point of view. Clin Transl Oncol 2008;10:713-8. [PMID: 19015067 DOI: 10.1007/s12094-008-0277-7] [Reference Citation Analysis]
78 Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013; 19(48): 9282-9293 [PMID: 24409055 DOI: 10.3748/wjg.v19.i48.9282] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
79 Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol 2015; 21(26): 7954-7969 [PMID: 26185368 DOI: 10.3748/wjg.v21.i26.7954] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
80 Wang L, Guo J, Wang Q, Zhou J, Xu C, Teng R, Chen Y, Wei Q, Liu ZP. LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of β-catenin. J Cancer Res Clin Oncol 2014;140:1997-2008. [PMID: 25005785 DOI: 10.1007/s00432-014-1753-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
81 Lordick F, Hoffmeister A. [Treatment of gastric cancer]. Internist (Berl) 2014;55:15-6, 18-22. [PMID: 24154498 DOI: 10.1007/s00108-013-3317-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
82 Brunner TB. [Is D2 and D1 lymphadenectomy for patients with gastric cancer beneficial?]. Strahlenther Onkol 2014;190:592-3. [PMID: 24967465 DOI: 10.1007/s00066-014-0623-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Li Y, Wang WB, Yang L, Wang QY, Dai J, Xia L, Peng J, Zhou FX, Wei YC, Shi HP. The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy. Nutrition 2021;93:111464. [PMID: 34678715 DOI: 10.1016/j.nut.2021.111464] [Reference Citation Analysis]
84 Huang ZN, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. BMC Cancer 2018;18:1064. [PMID: 30390644 DOI: 10.1186/s12885-018-4957-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
85 Lee J, Sohn I, Do IG, Kim KM, Park SH, Park JO, Park YS, Lim HY, Sohn TS, Bae JM, Choi MG, Lim DH, Min BH, Lee JH, Rhee PL, Kim JJ, Choi DI, Tan IB, Das K, Tan P, Jung SH, Kang WK, Kim S. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One. 2014;9:e90133. [PMID: 24598828 DOI: 10.1371/journal.pone.0090133] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
86 Goldfarb M, Brower S, Schwaitzberg SD. Minimally invasive surgery and cancer: controversies part 1. Surg Endosc. 2010;24:304-334. [PMID: 19572178 DOI: 10.1007/s00464-009-0583-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
87 Li G, Wang J, Hu W, Zhang Z. Radiation-Induced Liver Injury in Three-Dimensional Conformal Radiation Therapy (3D-CRT) for Postoperative or Locoregional Recurrent Gastric Cancer: Risk Factors and Dose Limitations. PLoS One 2015;10:e0136288. [PMID: 26291715 DOI: 10.1371/journal.pone.0136288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
88 Ratosa I, Oblak I, Anderluh F, Velenik V, But-Hadzic J, Ermenc AS, Jeromen A. Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer. Radiol Oncol. 2015;49:163-172. [PMID: 26029028 DOI: 10.2478/raon-2014-0027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
89 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 166] [Article Influence: 15.4] [Reference Citation Analysis]
90 Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012;33:749-756. [PMID: 22198641 DOI: 10.1007/s13277-011-0285-z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 6.4] [Reference Citation Analysis]
91 Chang JS, Choi Y, Shin J, Kim KH, Keum KC, Kim HS, Koom WS, Park EC. Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea. Cancer Res Treat 2018;50:118-28. [PMID: 28279066 DOI: 10.4143/crt.2016.575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
92 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
93 Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, Wu C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61:2251-2259. [PMID: 22674056 DOI: 10.1007/s00262-012-1289-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 7.8] [Reference Citation Analysis]
94 Ishido K, Higuchi K, Tanabe S, Azuma M, Sasaki T, Katada C, Komori S, Hayakawa K, Hosoda K, Yamashita K, Katada N, Koizumi W. Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. Jpn J Radiol 2016;34:35-42. [PMID: 26576774 DOI: 10.1007/s11604-015-0502-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
95 Li XH, He F, Yan SM, Li Y, Cao Y, Huang CY, Zhou ZW. Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. Med Oncol 2014;31:763. [PMID: 24258357 DOI: 10.1007/s12032-013-0763-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
96 Rajagopal I, Niveditha SR, Sahadev R, Nagappa PK, Rajendra SG. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. J Clin Diagn Res. 2015;9:EC06-EC10. [PMID: 25954623 DOI: 10.7860/jcdr/2015/12581.5630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
97 Hsieh CH, Hou ML, Wang LY, Tai HC, Tsai TH, Chen YJ. Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System. BMC Cancer 2015;15:316. [PMID: 25928348 DOI: 10.1186/s12885-015-1344-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
98 Huang ZN, Desiderio J, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer-an east and west multicenter study. BMC Gastroenterol 2019;19:205. [PMID: 31791240 DOI: 10.1186/s12876-019-1096-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
99 Liu C, Lu P, Lu Y, Xu H, Wang S, Chen J. Clinical implications of metastatic lymph node ratio in gastric cancer. BMC Cancer. 2007;7:200. [PMID: 17958880 DOI: 10.1186/1471-2407-7-200] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
100 Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A. Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS One 2017;12:e0183891. [PMID: 28922362 DOI: 10.1371/journal.pone.0183891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
101 Yang Q, Wei Y, Chen YX, Zhou SW, Jiang ZM, Xie DR. Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy. Gastroenterol Res Pract 2013;2013:634929. [PMID: 24194750 DOI: 10.1155/2013/634929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
102 Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, Pilanci KN. Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol 2016; 8(5): 439-449 [PMID: 27190583 DOI: 10.4251/wjgo.v8.i5.439] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
103 Sharma A, Radhakrishnan V. Gastric cancer in India. Indian J Med Paediatr Oncol 2021;32:12-6. [DOI: 10.4103/0971-5851.81884] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
104 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
105 Pelcovits A, Almhanna K. Locoregional gastric cancer: a narrative review of multidisciplinary management. Ann Transl Med 2020;8:1108. [PMID: 33145327 DOI: 10.21037/atm-20-3509] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
106 Miyazawa T, Ebe K, Koide N, Fujita N. Complete response of liver metastasis of gastric cancer treated by s-1 chemoradiotherapy: a case report. Case Rep Oncol Med 2012;2012:368428. [PMID: 22928135 DOI: 10.1155/2012/368428] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005;92:246-51. [PMID: 15655540 DOI: 10.1038/sj.bjc.6602336] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
108 Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg. 2005;29:1576-1584. [PMID: 16317484 DOI: 10.1007/s00268-005-7907-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
109 Baba H, Kuwabara K, Ishiguro T, Kumamoto K, Kumagai Y, Ishibashi K, Haga N, Ishida H. Prognostic factors for stage IV gastric cancer. Int Surg 2013;98:181-7. [PMID: 23701157 DOI: 10.9738/INTSURG-D-12-00027.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
110 Müller B, García C, Sola JA, Fernandez W, Werner P, Cerda M, Slater J, Benavides C, Arancibia J, Ascui R, Reyes F, Stevens MA, Miranda JP, Buchholtz M, Corvalan AH. Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice. Ecancermedicalscience 2021;15:1244. [PMID: 34267800 DOI: 10.3332/ecancer.2021.1244] [Reference Citation Analysis]
111 Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48-63. [PMID: 24216698 DOI: 10.3390/cancers5010048] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 11.3] [Reference Citation Analysis]
112 Chen S, Chen YB, Li YF, Feng XY, Zhou ZW, Yuan XH, Qian CN. Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients. World J Gastroenterol 2012; 18(29): 3910-3916 [PMID: 22876045 DOI: 10.3748/wjg.v18.i29.3910] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
113 Lacueva FJ, Oliver I, Costa D, Calpena R. To perform or not D2 extended lymphadenectomy in patients with gastric cancer in the West. Effectiveness and limits. Clin Transl Oncol 2006;8:139-41. [PMID: 16648110 DOI: 10.1007/s12094-006-0001-4] [Reference Citation Analysis]
114 Namysł-Kaletka A, Wydmanski J, Tukiendorf A, Bodusz D, Leszczynski W, Kawczynski R, Grabinska K, Polanowski P. Influence of interfraction motion on margins for radiotherapy of gastric cancer. Br J Radiol 2015;88:20140610. [PMID: 25668485 DOI: 10.1259/bjr.20140610] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
115 Aoyama T, Fujikawa H, Cho H, Ogata T, Shirai J, Hayashi T, Rino Y, Masuda M, Oba MS, Morita S. A methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective, randomized, controlled study. Am J Surg Pathol. 2015;39:266-273. [PMID: 25356528 DOI: 10.1097/pas.0000000000000336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
116 Sun Z, Zhu RJ, Yang GF, Li Y. Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. ScientificWorldJournal 2014;2014:418694. [PMID: 25136668 DOI: 10.1155/2014/418694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
117 Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015; 7(8): 102-110 [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
118 Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 2017;10:105. [PMID: 28494772 DOI: 10.1186/s13045-017-0473-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
119 Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI. Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol 2016;23:1203-11. [PMID: 26530447 DOI: 10.1245/s10434-015-4947-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
120 Li XK, Fan QX. Progress in medication treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
121 Kucuktulu E, Yurekli AF, Topbas M, Kece C, Guner A, Kucuktulu U. Comparisons between the Dosimetric and Clinical Outcomes of Tomotherapy and 3D Conformal Radiotherapy in Gastric Cancer Treatment. Asian Pac J Cancer Prev 2019;20:595-9. [PMID: 30806065 DOI: 10.31557/APJCP.2019.20.2.595] [Reference Citation Analysis]
122 Chang AT, Ng WT, Law AL, Ku KM, Lee MC, Lee AW. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63-71. [PMID: 21327926 DOI: 10.1007/s10120-011-0011-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
123 Chen HS, Hung WH, Ko JL, Hsu PK, Liu CC, Wu SC, Lin CH, Wang BY. Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. Medicine (Baltimore) 2016;95:e3018. [PMID: 26962818 DOI: 10.1097/MD.0000000000003018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Jomrich G, Schoppmann SF. Targeted therapy in gastric cancer. Eur Surg 2016;48:278-84. [PMID: 27795701 DOI: 10.1007/s10353-016-0389-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
125 Aggarwal A, Chopra S, Paul SN, Engineer R, Srivastava SK. Evaluation of internal target volume in patients undergoing image-guided intensity modulated adjuvant radiation for gastric cancers. Br J Radiol 2014;87:20130583. [PMID: 24288401 DOI: 10.1259/bjr.20130583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Keld RR, Ang YS. Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine? World J Gastroenterol 2011; 17(23): 2781-2790 [PMID: 21734785 DOI: 10.3748/wjg.v17.i23.2781] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
128 Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, Lin DJ, Shao CK, Liu Q. Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 2011;11:397. [PMID: 21933426 DOI: 10.1186/1471-2407-11-397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
129 Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010;21:78-86. [PMID: 19622587 DOI: 10.1093/annonc/mdp280] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
130 Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009; 1(1): 47-54 [PMID: 21160774 DOI: 10.4251/wjgo.v1.i1.47] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
131 Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep 2004;6:192-8. [PMID: 15066230 DOI: 10.1007/s11912-004-0049-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
132 Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34-42. [PMID: 23430266 DOI: 10.1007/s10120-013-0239-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
133 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
134 Yu DH, Tang L, Dong H, Dong Z, Zhang L, Fu J, Su X, Zhang T, Fu H, Han L, Xie L, Chen H, Qian Z, Zhu G, Wang J, Ye Q, Zhang J, Yin X, Zhang X, Ji J, Ji Q. Oncogenic HER2 fusions in gastric cancer. J Transl Med 2015;13:116. [PMID: 25889497 DOI: 10.1186/s12967-015-0476-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
135 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803-4810. [PMID: 22042947 DOI: 10.1200/jco.2011.35.4928] [Cited by in Crossref: 313] [Cited by in F6Publishing: 184] [Article Influence: 28.5] [Reference Citation Analysis]
136 Farooq F, Zarrabi K, Sweeney K, Kim J, Bandovic J, Patel C, Choi M. Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation. J Gastric Cancer 2018;18:200-7. [PMID: 29984070 DOI: 10.5230/jgc.2018.18.e16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Orhan O, Eroglu C, Kaplan B, Ucar K, Altinbas M, Ozkan M, Unal D, Yildiz OG, Soyuer S. Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer. J Radiat Res 2011;52:168-75. [PMID: 21343682 DOI: 10.1269/jrr.10075] [Reference Citation Analysis]
138 Aftimos PG, Nasr EA, Nasr DI, Noun RJ, Nasr FL, Ghosn MG, El Helou JA, Chahine GY. Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience. Radiat Oncol 2010;5:50. [PMID: 20525367 DOI: 10.1186/1748-717X-5-50] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Özçelik M, Ercelep Ö, Keser S, Özdemir Barışık N, Başar M, Odabaş H, Oyman A, Işık S, Özçelik S, Aliustaoğlu M. PTK-7 Expression in Gastric Cancer: A Prognostic Determinant. Balkan Med J 2020;37:91-7. [PMID: 31820857 DOI: 10.4274/balkanmedj.galenos.2019.2019.8.12] [Reference Citation Analysis]
140 Peng J, Gong J, Wang X, Mou J, Xu H, Dai J, Zhou F, Zhou Y. 4-Dimensional computed tomography analysis of clinical target volume displacement in adjuvant radiation of patients with gastric cancer and its implication on radiotherapy. Oncol Lett 2019;17:3641-8. [PMID: 30881488 DOI: 10.3892/ol.2019.10037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Zhao JH, Gao P, Song YX, Sun JX, Chen XW, Ma B, Yang YC, Wang ZN. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. BMC Cancer 2016;16:631. [PMID: 27519527 DOI: 10.1186/s12885-016-2667-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
142 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
143 Mastoraki S, Mastoraki A, Lefantzis N, Safioleas P, Sakorafas G, Safioleas M. Controversies and challenging therapeutic modalities in gastric cancer. Indian J Surg 2011;73:251-5. [PMID: 22851836 DOI: 10.1007/s12262-011-0285-7] [Reference Citation Analysis]
144 Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581. [PMID: 21431408 DOI: 10.1245/s10434- 011-1631-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Batista TP, Martins MR. Lymph node dissection for gastric cancer: a critical review. Oncol Rev 2012;6:e12. [PMID: 25992202 DOI: 10.4081/oncol.2012.e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
146 Zhang Y, Yu Z, Xiao Q, Sun X, Zhu Z, Zhang J, Xu H, Wei M, Sun M. Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer. Tumour Biol 2014;35:7047-56. [PMID: 24752577 DOI: 10.1007/s13277-014-1962-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
147 Nishibeppu K, Komatsu S, Ichikawa D, Imamura T, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer. BMC Cancer 2018;18:108. [PMID: 29382310 DOI: 10.1186/s12885-018-4052-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
148 Liakakos T. Laparoscopic gastrectomy: feasibility, safety and efficacy. Ann Surg Oncol 2008;15:1249-50. [PMID: 18027056 DOI: 10.1245/s10434-007-9689-9] [Reference Citation Analysis]
149 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
150 Qu JL, Li X, Qu XJ, Zhu ZT, Zhou LZ, Teng YE, Zhang JD, Jin B, Zhao MF, Yu P, Liu YP. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One 2013;8:e83196. [PMID: 24386161 DOI: 10.1371/journal.pone.0083196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
151 Zhong Q, Xiao ZY, Wu RR, Zhong H, Deng JH, Zeng AQ. Efficacy and safety of intensity-modulated radiation therapy combined with gimeracil and oteracil potassium capsules in patients with advanced gastric cancer after surgery: a controlled clinical study. Shijie Huaren Xiaohua Zazhi 2011; 19(36): 3700-3704 [DOI: 10.11569/wcjd.v19.i36.3700] [Reference Citation Analysis]
152 Soyfer V, Geva R, Michelson M, Inbar M, Shacham-Shmueli E, Corn BW. The impact of overall radiotherapy treatment time and delay in initiation of radiotherapy on local control and distant metastases in gastric cancer. Radiat Oncol 2014;9:81. [PMID: 24655942 DOI: 10.1186/1748-717X-9-81] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
153 Park JS, Yu JI, Lim DH, Nam H, Kim YI, Lee J, Kang WK, Park SH, Kim ST, Hong JY, Sohn TS, Lee JH, An JY, Choi MG, Bae JM. Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. Cancers (Basel) 2020;13:E59. [PMID: 33379195 DOI: 10.3390/cancers13010059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 243] [Article Influence: 27.7] [Reference Citation Analysis]
155 Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, Hyung WJ, Fong Y, Paz IB, Woo Y. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019;4:42. [PMID: 31231709 DOI: 10.21037/tgh.2019.05.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
156 Dixon M, Palter V, Brar S, Coburn N. Evaluating quality and completeness of gastrectomy for gastric cancer: review of surgical videos from the public domain. Transl Gastroenterol Hepatol 2021;6:57. [PMID: 34805579 DOI: 10.21037/tgh.2020.01.01] [Reference Citation Analysis]
157 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
158 Kim IH. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 2019; 11(9): 679-685 [PMID: 31558973 DOI: 10.4251/wjgo.v11.i9.679] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
159 Yang Y, Qu A, Zhao R, Hua M, Zhang X, Dong Z, Zheng G, Pan H, Wang H, Yang X, Zhang Y. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018;12:2072-2084. [PMID: 30242969 DOI: 10.1002/1878-0261.12385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
160 Wu DM, Wang S, Wen X, Han XR, Wang YJ, Shen M, Fan SH, Zhang ZF, Zhuang J, Shan Q, Li MQ, Hu B, Sun CH, Lu J, Zheng YL. Survival Benefit of Three Different Therapies in Postoperative Patients With Advanced Gastric Cancer: A Network Meta-Analysis. Front Pharmacol 2018;9:929. [PMID: 30210338 DOI: 10.3389/fphar.2018.00929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 González-Domingo M, Ulloa C, Olivares J, Estrada S, González P, Cardozo N. Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. Ecancermedicalscience 2020;14:1137. [PMID: 33281929 DOI: 10.3332/ecancer.2020.1137] [Reference Citation Analysis]
162 Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res 2018;7:F1000 Faculty Rev-1365. [PMID: 30228868 DOI: 10.12688/f1000research.15133.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
163 Li W, Wong CC, Zhang X, Kang W, Nakatsu G, Zhao Q, Chen H, Go MYY, Chiu PWY, Wang X, Ji J, Li X, Cai Z, Ng EKW, Yu J. CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis. Oncogene 2018;37:6383-98. [PMID: 30054562 DOI: 10.1038/s41388-018-0402-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
164 Foo M, Leong T. Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol 2014; 20(38): 13718-13727 [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
165 Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH. Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. J Gastrointest Oncol 2016;7:506-14. [PMID: 27563439 DOI: 10.21037/jgo.2016.06.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
166 Ruspi L, Galli F, Frattini F, Peverelli C, Di Rocco G, Martignoni F, Rovera F, Boni L, Dionigi G, Rausei S. A “perfect” lymph node staging system requires a “perfect” surgery. Transl Gastroenterol Hepatol. 2016;1:10. [PMID: 28138577 DOI: 10.21037/tgh.2016.01.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
167 Rivera F, Grávalos C, García-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol. 2012;14:528-535. [PMID: 22721798 DOI: 10.1007/s12094-012-0836-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
168 Zhou ML, Li GC, Yang W, Deng WJ, Hu R, Wang Y, Long ZW, Liu XW, Wang YN, Zhang Z. Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study. Br J Radiol 2018;91:20180276. [PMID: 29906235 DOI: 10.1259/bjr.20180276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18:877. [PMID: 30200910 DOI: 10.1186/s12885-018-4770-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
170 Miao RL, Wu AW. Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol 2014; 20(33): 11586-11594 [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
171 Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer 2017;20:135-40. [PMID: 27718134 DOI: 10.1007/s10120-016-0654-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
172 Mokadem I, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP, van Laarhoven HWM, Verhoeven RHA. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 2019;. [PMID: 30949777 DOI: 10.1007/s10120-019-00956-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
173 Khosravi Shahi P, Díaz Muñoz de la Espada VM, García Alfonso P, Encina García S, Izarzugaza Perón Y, Arranz Cozar JL, Hernández Marín B, Pérez Manga G. Management of gastric adenocarcinoma. Clin Transl Oncol 2007;9:438-42. [PMID: 17652057 DOI: 10.1007/s12094-007-0082-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
174 Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, Ajani JA, You YN. Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. J Surg Oncol 2018;117:707-9. [PMID: 29228462 DOI: 10.1002/jso.24926] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
175 Yu WW, Fu XL, Cai XW, Sun MH, Guo YM. Identification of differentially expressed proteins in the locoregional recurrent esophageal squamous cell carcinoma by quantitative proteomics. J Gastrointest Oncol 2021;12:991-1006. [PMID: 34295551 DOI: 10.21037/jgo-21-278] [Reference Citation Analysis]
176 Wang Q, Peng L, Han Y, Li T, Dai W, Wang Y, Wu L, Wei Y, Xie T, Fang Q, Li Q, Lang J, Cao B. Preoperative Serum Sodium Level as a Prognostic and Predictive Biomarker for Adjuvant Therapy in Esophageal Cancer. Front Oncol 2020;10:555714. [PMID: 33552948 DOI: 10.3389/fonc.2020.555714] [Reference Citation Analysis]
177 Tamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745. [PMID: 22312521 DOI: 10.1155/2011/748745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
178 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
179 Gu L, Zhang Y, Hong J, Xu B, Yang L, Yan K, Zhang J, Chen P, Zheng J, Lin J. Prognostic Value of Pretreatment Overweight/Obesity and Adipose Tissue Distribution in Resectable Gastric Cancer: A Retrospective Cohort Study. Front Oncol 2021;11:680190. [PMID: 34249721 DOI: 10.3389/fonc.2021.680190] [Reference Citation Analysis]
180 Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11. [PMID: 22811814 DOI: 10.3978/j.issn.2078-6891.2010.013] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
181 Shulman K, Haim N, Wollner M, Bernstein Z, Abdah-Bortnyak R, Bar-Sela G. Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study. Oncol Lett 2012;3:1154-8. [PMID: 22783410 DOI: 10.3892/ol.2012.617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
182 Chen G, Jiao ZY. Challenge and thought on treatment of diffuse gastric cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(17): 2608-2616 [DOI: 10.11569/wcjd.v24.i17.2608] [Reference Citation Analysis]
183 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Allum W, Garofalo A, Degiuli M, Schuhmacher C. The first European Union Network of Excellence for Gastric Cancer conference, Rome, Italy, April 2008. Gastric Cancer 2009;12:56-65. [PMID: 19390934 DOI: 10.1007/s10120-009-0499-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
185 Scartozzi M, Pistelli M, Bittoni A, Giampieri R, Galizia E, Berardi R, Faloppi L, Del Prete M, Cascinu S. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr Oncol Rep 2010;12:175-85. [PMID: 20425077 DOI: 10.1007/s11912-010-0101-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
186 Ngoc Thi Dang D, Ngoc Thi Nguyen L, Thi Dang N, Quang Dang H, Ta TV. Quality of Life in Vietnamese Gastric Cancer Patients. Biomed Res Int 2019;2019:7167065. [PMID: 31236411 DOI: 10.1155/2019/7167065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
187 Hisashige A, Sasako M, Nakajima T. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer. 2013;13:443. [PMID: 24079752 DOI: 10.1186/1471-2407-13-443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
188 Hundahl SA. The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma. Gastric Cancer. 2012;15:3-4. [PMID: 22160297 DOI: 10.1007/s10120-011-0121-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
189 Wang SB, Qi WX, Chen JY, Xu C, Cao WG, Cai R, Cao L, Cai G. Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis. Front Oncol 2021;11:648978. [PMID: 33869049 DOI: 10.3389/fonc.2021.648978] [Reference Citation Analysis]
190 Toneto MG, Viola L. CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1373. [PMID: 29972401 DOI: 10.1590/0102-672020180001e1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
191 Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015; 7(12): 389-400 [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
192 Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006;243:334-40. [PMID: 16495697 DOI: 10.1097/01.sla.0000201452.09591.f3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
193 Wang ZX, Yang XL, He MM, Wang F, Zhang DS, Li YH, Zhou ZW, Zhan YQ, Xu RH. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis. Medicine (Baltimore) 2016;95:e3214. [PMID: 27100411 DOI: 10.1097/MD.0000000000003214] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
194 Zhang T, Liang ZW, Han J, Bi JP, Yang ZY, Ma H. Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. Radiat Oncol 2015;10:114. [PMID: 25986069 DOI: 10.1186/s13014-015-0420-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
195 de Jesus VHF, da Costa WL Jr, Felismino TC, Calsavara VF, Diniz AL, de Castro Ribeiro HS, de Godoy AL, de Farias IC, Coimbra FJF. Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method. J Gastrointest Oncol 2019;10:1110-9. [PMID: 31949928 DOI: 10.21037/jgo.2019.10.04] [Reference Citation Analysis]
196 Souza FO, Pereira DV, Santos LH, Antunes L, Chiesa J. Gastric cancer patients treated by a general or gastric cancer surgical team: a comparative study. Arq Gastroenterol 2008;45:28-33. [PMID: 18425225 DOI: 10.1590/s0004-28032008000100006] [Reference Citation Analysis]
197 Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-133. [PMID: 29239137 DOI: 10.1002/cam4.1274] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 14.4] [Reference Citation Analysis]
198 Lv XG, Lei XF, Ji MY, Guo XF, Wang J, Dong WG. Clinical significance of EBP50 overexpression assessed by quantum dot analysis in gastric cancer. Oncol Lett 2013;5:1844-8. [PMID: 23833653 DOI: 10.3892/ol.2013.1271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
199 Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019;37:1296-1304. [PMID: 30925125 DOI: 10.1200/jco.18.01138] [Cited by in Crossref: 80] [Cited by in F6Publishing: 45] [Article Influence: 26.7] [Reference Citation Analysis]
200 Wang X, Tian Y, Tang Y, Hu ZH, Zhang JJ, Fu GS, Ma P, Ren H, Zhang T, Li N, Liu WY, Fang H, Li YX, Jin J. Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy.Oncotarget. 2017;8:39727-39735. [PMID: 28061474 DOI: 10.18632/oncotarget.14459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
201 Jin P, Ji X, Ma S, Kang W, Liu H, Li Y, Ma F, Hu H, Li W, Tian Y. Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience. J Cancer Res Clin Oncol 2021;147:561-8. [PMID: 32772233 DOI: 10.1007/s00432-020-03355-y] [Reference Citation Analysis]
202 Zaidi A, Khan A, Duval C, Haider K, Ahmed O, Dueck DA, Brunet B, Gardiner D, Ahmed S. Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience. Curr Oncol 2021;28:1262-73. [PMID: 33802661 DOI: 10.3390/curroncol28020120] [Reference Citation Analysis]
203 Tianhang L, Guoen F, Jianwei B, Liye M. The effect of perineural invasion on overall survival in patients with gastric carcinoma. J Gastrointest Surg. 2008;12:1263-1267. [PMID: 18463928 DOI: 10.1007/s11605-008-0529-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
204 Batista TP, de Mendonça LM, Fassizoli-Fonte AL. The role of perioperative radiotherapy in gastric cancer. Oncol Rev 2012;6:e23. [PMID: 25992221 DOI: 10.4081/oncol.2012.e23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
205 Yeh JM, Tramontano AC, Hur C, Schrag D. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer 2017;20:811-24. [PMID: 28205057 DOI: 10.1007/s10120-017-0693-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
206 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014;110:1163-1168. [PMID: 24473399 DOI: 10.1038/bjc.2014.18] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 10.6] [Reference Citation Analysis]
208 Liang B, Zheng W, Fang L, Wu L, Zhou F, Yin X, Yu X, Zou Z. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biol Ther. 2016;17:824-832. [PMID: 27314162 DOI: 10.1080/15384047.2016.1195046] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
209 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
210 Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol. 2011;2:334-342. [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
211 Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 2014;14:984. [PMID: 25526802 DOI: 10.1186/1471-2407-14-984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
212 Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017;47:899-907. [PMID: 28247105 DOI: 10.1007/s00595-017-1473-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
213 Yang H, Ji X, Jin C, Ji K, Jia Z, Wu X, Zhang J, Bu Z. A Practical Nomogram for Predicting the Prognosis of Elderly Patients with Gastric Adenocarcinoma After Gastrectomy. IJGM 2022;Volume 15:473-88. [DOI: 10.2147/ijgm.s343306] [Reference Citation Analysis]
214 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647 [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
215 Zhang Y, Zhang Q, Zhang M, Yuan M, Wang Z, Zhang J, Zhou X, Zhang Y, Lin F, Na H, Ren S, Zuo Y. DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis. Mol Cancer 2017;16:78. [PMID: 28403883 DOI: 10.1186/s12943-017-0639-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
216 Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, Sakuramoto S, Kikuchi S, Watanabe M. Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today. 2015;45:68-77. [PMID: 25352012 DOI: 10.1007/s00595-014-1060-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
217 Zhou Y, Zhang J, Cao S, Li Y. The evaluation of metastatic lymph node ratio staging system in gastric cancer. Gastric Cancer. 2013;16:309-317. [PMID: 22945599 DOI: 10.1007./s10120-012-0190-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Jin P, Liu H, Ma FH, Ma S, Li Y, Xiong JP, Kang WZ, Hu HT, Tian YT. Retrospective analysis of surgically treated pT4b gastric cancer with pancreatic head invasion . World J Clin Cases 2021; 9(29): 8718-8728 [PMID: 34734050 DOI: 10.12998/wjcc.v9.i29.8718] [Reference Citation Analysis]
219 Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer 2016;19:586-96. [PMID: 25851942 DOI: 10.1007/s10120-015-0490-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
220 Dixit S, Tilston M, Peter WM. Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. Med Oncol. 2010;27:242-248. [PMID: 19308739 DOI: 10.1007/s12032-009-9199-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
221 Knab LM, Yang A. Gastric and Small Bowel Tumors. Cancer Treat Res 2016;168:1-16. [PMID: 29206015 DOI: 10.1007/978-3-319-34244-3_1] [Reference Citation Analysis]
222 Nelson R, Ko EB, Arrington A, Lee W, Kim J, Garcia-Aguilar J, Kim J. Race and correlations between lymph node number and survival for patients with gastric cancer. J Gastrointest Surg. 2013;17:471-481. [PMID: 23288716 DOI: 10.1007/s11605-012-2125-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
223 He RB, Chen JQ. Research progress in neoadjuvant chemotherapy for gastric cancer. Shijie Huaren Xiaohua Zazhi 2009; 17(12): 1207-1211 [DOI: 10.11569/wcjd.v17.i12.1207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
224 van Lanschot JJB, Noordman BJ. Response to Letter: "Radiation Is Not a Solution for Suboptimal Surgery. A Response to the Conclusions Drawn From the Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma With or Without Neoadjuvant Chemoradiotherapy Study". Ann Surg 2019;270:e14-5. [PMID: 30247326 DOI: 10.1097/SLA.0000000000003026] [Reference Citation Analysis]
225 Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20:60-68. [PMID: 28039533 DOI: 10.1007/s10120-016-0685-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
226 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175bjc2011175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
227 Johnstone PA. Foreword. Continued debate regarding optimal surgery, radiation techniques, and chemotherapy regimens. Curr Probl Cancer 2011;35:96. [PMID: 21635985 DOI: 10.1016/j.currproblcancer.2011.04.001] [Reference Citation Analysis]
228 Ben Salah H, Bahri M, Dhouib F, Daoud J. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction]. Cancer Radiother 2016;20:830-2. [PMID: 27793531 DOI: 10.1016/j.canrad.2016.07.100] [Reference Citation Analysis]
229 Zhang S, Liu Y, Jiao Z, Li Z, Wang J, Li C, Qu X, Xu L. Development and Validation of a Prognostic Nomogram for Gastric Signet Ring Cell Carcinoma: A Multicenter Population-Based Study. Front Oncol 2021;11:603031. [PMID: 33763350 DOI: 10.3389/fonc.2021.603031] [Reference Citation Analysis]
230 Onal C, Cengiz M, Guler OC, Dolek Y, Ozkok S. The role of delineation education programs for improving interobserver variability in target volume delineation in gastric cancer. Br J Radiol 2017;90:20160826. [PMID: 28339289 DOI: 10.1259/bjr.20160826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
231 Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J. Gastric Cancer. 2013;13:73-78. [PMID: 23844320 DOI: 10.5230/jgc.2013.13.2.73] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
232 Lee SE, Hong M, Cho J, Lee J, Kim KM. IKKε and TBK1 expression in gastric cancer. Oncotarget 2017;8:16233-42. [PMID: 27145266 DOI: 10.18632/oncotarget.9069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
233 Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol 2014;7:472-8. [PMID: 24956939 DOI: 10.1016/j.tranon.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
234 Chang JS, Koom WS, Lee Y, Yoon HI, Lee HS. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection? World J Gastroenterol 2014; 20(36): 12900-12907 [PMID: 25278687 DOI: 10.3748/wjg.v20.i36.12900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
235 Fan M, Hu W, Zhang Z. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol 2015;88:20150027. [PMID: 25827208 DOI: 10.1259/bjr.20150027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
236 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
237 Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105:1600-1607. [PMID: 24108812 DOI: 10.1093/jnci/djt270] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 9.6] [Reference Citation Analysis]
238 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Cao J, Gong J, Li X, Hu Z, Xu Y, Shi H, Li D, Liu G, Jie Y, Hu B, Chong Y. Unsupervised Hierarchical Clustering Identifies Immune Gene Subtypes in Gastric Cancer. Front Pharmacol 2021;12:692454. [PMID: 34248641 DOI: 10.3389/fphar.2021.692454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
240 Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, Pramesh CS, Gilbert D, Kynaston H, Cameron D. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56-64. [PMID: 27777129 DOI: 10.1016/j.cct.2016.10.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 13.2] [Reference Citation Analysis]
241 Lee J, An JY, Choi MG, Park SH, Kim ST, Lee JH, Sohn TS, Bae JM, Kim S, Lee H, Min BH, Kim JJ, Jeong WK, Choi DI, Kim KM, Kang WK, Kim M, Seo SW. Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. JCO Clin Cancer Inform 2018;2:1-14. [PMID: 30652558 DOI: 10.1200/CCI.17.00065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
242 Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. J Cancer Res Clin Oncol 2019;145:2365-73. [PMID: 31280347 DOI: 10.1007/s00432-019-02971-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
243 Wilke H, Stahl M. [Therapy in gastric cancer. From an oncological perspective]. Chirurg. 2009;80:1023-1027. [PMID: 19902288 DOI: 10.1007/s00104-009-1735-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
244 Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric Cancer Treatments and Survival Trends in the United States. Curr Oncol 2020;28:138-51. [PMID: 33704182 DOI: 10.3390/curroncol28010017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
245 Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, Bokemeyer C, Simon R, Sauter G, Marx AH. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol 2015;15:7. [PMID: 25649416 DOI: 10.1186/s12876-015-0231-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 10.0] [Reference Citation Analysis]
246 Liao F, Yang Z, Lu X, Guo X, Dong W. Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo.. Oncol Lett 2013;6:1604-10. [PMID: 24260052 DOI: 10.3892/ol.2013.1592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
247 Proserpio I, Rausei S, Barzaghi S, Frattini F, Galli F, Iovino D, Rovera F, Boni L, Dionigi G, Pinotti G. Multimodal treatment of gastric cancer. World J Gastrointest Surg 2014; 6(4): 55-58 [PMID: 24829622 DOI: 10.4240/wjgs.v6.i4.55] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
248 Wang X, Wang WH, Wang SL, Song YW, Liu YP, Tang Y, Li N, Liu WY, Fang H, Li YX, Zhao DB, Chi Y, Yang L, Jin J. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World J Gastrointest Oncol 2021; 13(10): 1532-1543 [PMID: 34721783 DOI: 10.4251/wjgo.v13.i10.1532] [Reference Citation Analysis]
249 Straatman J, van der Wielen N, Cuesta MA, Gisbertz SS, Hartemink KJ, Alonso Poza A, Weitz J, Mateo Vallejo F, Ahktar K, Diez Del Val I. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): study protocol for a randomized controlled trial. Trials. 2015;16:123. [PMID: 25873249 DOI: 10.1186/s13063-015-0638-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
250 Hanisch E, Ziogas D, Roukos D, Hottenrott C. Advances in laparoscopic gastrectomy expand clinical use. Ann Surg Oncol 2008;15:1251-2. [PMID: 18058181 DOI: 10.1245/s10434-007-9721-0] [Reference Citation Analysis]
251 Ishida K, Ito C, Ohmori Y, Kume K, Sato KA, Koizumi Y, Konta A, Iwaya T, Nukatsuka M, Kobunai T, Takechi T, Nishizuka SS. Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. Sci Rep 2017;7:2262. [PMID: 28536445 DOI: 10.1038/s41598-017-02548-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
252 Das P. Esophageal cancer: Is preoperative chemoradiation the new standard? J Gastrointest Oncol 2010;1:68-9. [PMID: 22811807 DOI: 10.3978/j.issn.2078-6891.2010.014] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
253 Yi H, Yan X, Luo Q, Yuan L, Li B, Pan W, Zhang L, Chen H, Wang J, Zhang Y, Zhai Y, Qiu MZ, Yang DJ. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. J Exp Clin Cancer Res 2018;37:97. [PMID: 29716622 DOI: 10.1186/s13046-018-0765-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
254 Ishigami H, Tsuji Y, Shinohara H, Kodera Y, Kanda M, Yabusaki H, Ito S, Imano M, Yamashita H, Hidemura A, Yamaguchi H, Fukagawa T, Oba K, Kitayama J, Seto Y. Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. J Clin Med 2021;10:5666. [PMID: 34884367 DOI: 10.3390/jcm10235666] [Reference Citation Analysis]
255 Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50:30-37. [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
256 Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg. 2010;395:217-225. [PMID: 20012317 DOI: 10.1007/s00423-009-0573-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
257 Lieto E, Auricchio A, Tirino G, Pompella L, Panarese I, Del Sorbo G, Ferraraccio F, De Vita F, Galizia G, Cardella F. Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers (Basel) 2021;13:4676. [PMID: 34572903 DOI: 10.3390/cancers13184676] [Reference Citation Analysis]
258 Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer 2014;17:287-93. [PMID: 23712439 DOI: 10.1007/s10120-013-0270-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
259 Huang Z, Li S, Yang X, Lu F, Huang M, Zhang S, Xiong Y, Zhang P, Si J, Ma Y, Yang Y. Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study. Cancer Manag Res 2019;11:1299-308. [PMID: 30799956 DOI: 10.2147/CMAR.S195355] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Buffart TE, Carvalho B, van Grieken NC, van Wieringen WN, Tijssen M, Kranenbarg EM, Verheul HM, Grabsch HI, Ylstra B, van de Velde CJ, Meijer GA. Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist 2012;17:653-62. [PMID: 22531355 DOI: 10.1634/theoncologist.2010-0379] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
261 Shih WT, Yang PR, Chen KJ, Yang YH, Lu ML, Chen VC, Shen YC. Antidepressants use is associated with overall survival improvement of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: A large population-based cohort study. Medicine (Baltimore) 2021;100:e27031. [PMID: 34449480 DOI: 10.1097/MD.0000000000027031] [Reference Citation Analysis]
262 Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol 2012;3:209-25. [PMID: 22943012 DOI: 10.3978/j.issn.2078-6891.2012.024] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
263 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
264 Wang YN, Chang SY, Hwang JM, Chang YK, Kao WY, Wan HL, Tzeng IS, Wu CC. Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. Tzu Chi Med J 2021;33:288-93. [PMID: 34386368 DOI: 10.4103/tcmj.tcmj_230_20] [Reference Citation Analysis]
265 Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, Lu J, Yang J, Zhu R, Zhang H, Zhou Y, Xu L, Guo C. The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS One 2014;9:e97414. [PMID: 24816638 DOI: 10.1371/journal.pone.0097414] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
266 Russo A, Strong VE. Minimally invasive surgery for gastric cancer in USA: current status and future perspectives. Transl Gastroenterol Hepatol.  2017; 30(2):38. E collection.. [PMID: 28529992 DOI: 10.21037/tgh.2017.03.14] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
267 Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T, Noh SH, Fong Y, Hyung WJ. Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. J Am Coll Surg 2017;224:546-55. [PMID: 28017807 DOI: 10.1016/j.jamcollsurg.2016.12.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
268 Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761. [PMID: 23524864 DOI: 10.1093/annonc/mdt106] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
269 Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM, Do YR, Kwon KY, Song HS. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean J Intern Med 2005;20:135-40. [PMID: 16134768 DOI: 10.3904/kjim.2005.20.2.135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
270 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Lim JB, Kim DK, Chung HW. Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker. Cancer Sci 2014;105:1327-33. [PMID: 25154912 DOI: 10.1111/cas.12505] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
272 Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach.Front Surg. 2017;4:42. [PMID: 28824918 DOI: 10.3389/fsurg.2017.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
273 Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39-48. [PMID: 25553082 DOI: 10.1177/1758834014558839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
274 Lee JY, Son T, Cheong JH, Hyung WJ, Noh SH, Kim CB, Park CG, Kim HI. Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study. J Gastric Cancer. 2015;15:223-230. [PMID: 26819801 DOI: 10.5230/jgc.2015.15.4.223] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
275 Wang X, Jin J, Li YX, Ren H, Fang H, Wang SL, Liu YP, Wang WH, Yu ZH, Song YW, Liu XF. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol 2014; 20(4): 1067-1073 [PMID: 24574780 DOI: 10.3748/wjg.v20.i4.1067] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
276 Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 2013;14:311-320. [PMID: 23686725 DOI: 10.1007/s11864-013-0238-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
277 Kleinberg L. Does postoperative radiation therapy benefit patients with esophageal cancer? J Gastrointest Oncol 2010;1:70-1. [PMID: 22811808 DOI: 10.3978/j.issn.2078-6891.2010.015] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
278 Onal C, Dölek Y, AkkuşYıldırım B. Dosimetric comparison of 3-dimensional conformal radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for postoperative gastric cancer patients.Jpn J Radiol. 2018;36:30-39. [PMID: 29101643 DOI: 10.1007/s11604-017-0696-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
279 Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-393. [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
280 Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol 2011;2:240-9. [PMID: 22811858 DOI: 10.3978/j.issn.2078-6891.2011.027] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
281 Yan S, He F, Luo R, Wu H, Huang M, Huang C, Li Y, Zhou Z. Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma. Tumour Biol 2016;37:6125-33. [PMID: 26611647 DOI: 10.1007/s13277-015-3983-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
282 Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, Santos M, Lopes F, Maio R. Towards curative therapy in gastric cancer: Faraway, so close!. World J Gastroenterol 2015; 21(41): 11609-11620 [PMID: 26556990 DOI: 10.3748/wjg.v21.i41.11609] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
283 Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 2020; 12(1): 37-53 [PMID: 31966912 DOI: 10.4251/wjgo.v12.i1.37] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
284 Yang ZL, Zhu MH, Shi Q, Lu FM, Wang CX. Prognostic Value of the Number of Lymph Nodes Examined in Patients with Node-Negative Gastric Cancer. J Gastrointest Surg 2019;23:460-7. [PMID: 30225793 DOI: 10.1007/s11605-018-3947-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
285 Syrios J, Sougioultzis S, Xynos ID, Kavantzas N, Kosmas C, Agrogiannis G, Griniatsos J, Karavokyros I, Pikoulis E, Patsouris ES, Tsavaris N. Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer 2012;12:264. [PMID: 22892134 DOI: 10.1186/1471-2407-12-264] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
286 Yan SM, Tang JJ, Huang CY, Xi SY, Huang MY, Liang JZ, Jiang YX, Li YH, Zhou ZW, Ernberg I, Wu QL, Du ZM. Reduced expression of ZDHHC2 is associated with lymph node metastasis and poor prognosis in gastric adenocarcinoma. PLoS One 2013;8:e56366. [PMID: 23457560 DOI: 10.1371/journal.pone.0056366] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
287 Liakakos T, Xeropotamos N, Ziogas D, Roukos D. EGFR as a Prognostic Marker for Gastric Cancer. World J Surg. 2008;32:1225-1226; author reply 1227-1229. [PMID: 18224475 DOI: 10.1007/s00268-007-9434-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
288 Han JM, Sohng JK, Lee WH, Oh TJ, Jung HJ. Identification of Cyclophilin A as a Potential Anticancer Target of Novel Nargenicin A1 Analog in AGS Gastric Cancer Cells. Int J Mol Sci 2021;22:2473. [PMID: 33804393 DOI: 10.3390/ijms22052473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
289 Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
290 Lee HS, Choi Y, Hur WJ, Kim HJ, Kwon HC, Kim SH, Kim JS, Lee JH, Jung GJ, Kim MC. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol 2006; 12(4): 603-607 [PMID: 16489675 DOI: 10.3748/wjg.v12.i4.603] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
291 Taki T, Hoya Y, Watanabe A, Nakayoshi T, Okamoto T, Sekine H, Mitsumori N, Yanaga K. Usefulness of chemoradiotherapy for inoperable gastric cancer. Ann R Coll Surg Engl 2017;99:332-6. [PMID: 27659357 DOI: 10.1308/rcsann.2016.0305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
292 Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy vs Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019;10:458-466. [PMID: 30719140 DOI: 10.7150/jca.27335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
293 Andreollo NA, Drizlionoks E, Tercioti-Junior V, Coelho-Neto JS, Ferrer JAP, Carvalheira JBC, Lopes LR. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? Arq Bras Cir Dig 2019;32:e1464. [PMID: 31859917 DOI: 10.1590/0102-672020190001e1464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
294 Yang W, Hu R, Li GC, Zhou ML, Wang Y, Shen LJ, Liang LP, Zhang Z. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study. Br J Radiol 2018;91:20170594. [PMID: 29927628 DOI: 10.1259/bjr.20170594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
295 Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002;86:1864-1870. [PMID: 12085177 DOI: 10.1038/sj.bjc.6600310] [Cited by in Crossref: 184] [Cited by in F6Publishing: 159] [Article Influence: 9.2] [Reference Citation Analysis]
296 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
297 Xue SL, Su HF, Hu XQ, Deng X, Hu ML, Xie CY. Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer. Oncol Lett 2012;4:1309-14. [PMID: 23205128 DOI: 10.3892/ol.2012.914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
298 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
299 Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 2021;39:2903-13. [PMID: 34133211 DOI: 10.1200/JCO.20.02914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, Yamasaki M, Takiguchi S, Mori M, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer 2018;21:446-52. [PMID: 28965205 DOI: 10.1007/s10120-017-0767-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
301 Willett CG, Moughan J, O'Meara E, Galvin JM, Crane CH, Winter K, Manfredi D, Rich TA, Rabinovitch R, Lustig R, Machtay M, Curran WJ. Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials. Radiother Oncol 2012;105:9-13. [PMID: 23084596 DOI: 10.1016/j.radonc.2012.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
302 Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev 2016;7:CD011461. [PMID: 27432490 DOI: 10.1002/14651858.CD011461.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
303 Tyczyńska M, Kędzierawski P, Karakuła K, Januszewski J, Kozak K, Sitarz M, Forma A. Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review. J Gastrointest Cancer 2021;52:476-88. [PMID: 33761051 DOI: 10.1007/s12029-021-00629-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
304 Zhu Y, Yang W, Ji G, Lin N, Wu W, Xiong P, Zheng C, Yan L, Wan P, Wang Y. Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma. Oncotarget 2017;8:31092-100. [PMID: 28415703 DOI: 10.18632/oncotarget.16087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
305 Chon SH, Berlth F, Plum PS, Herbold T, Alakus H, Kleinert R, Moenig SP, Bruns CJ, Hoelscher AH, Meyer HJ. Gastric cancer treatment in the world: Germany. Transl Gastroenterol Hepatol 2017;2:53. [PMID: 28616608 DOI: 10.21037/tgh.2017.05.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
306 Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161 [PMID: 23599641 DOI: 10.3748/wjg.v19.i14.2154] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
307 Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014;31:906. [PMID: 24627237 DOI: 10.1007/s12032-014-0906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
308 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
309 Arai H, Sunakawa Y, Nakajima TE. Co-operative groups in the development of chemotherapy for gastric cancer. Jpn J Clin Oncol 2019;49:210-27. [PMID: 30508188 DOI: 10.1093/jjco/hyy176] [Reference Citation Analysis]
310 Yuan XL, Fu Q, Hu GQ, Chen Y, Zhang LH, Hu GY, Yu SY. Postoperative sequence chemoradiotherapy for advanced gastric cancer: an analysis of 36 cases. Shijie Huaren Xiaohua Zazhi 2007; 15(36): 3856-3859 [DOI: 10.11569/wcjd.v15.i36.3856] [Reference Citation Analysis]
311 Snyder RA, Penson DF, Ni S, Koyama T, Merchant NB. Trends in the use of evidence-based therapy for resectable gastric cancer. J Surg Oncol 2014;110:285-90. [PMID: 24891231 DOI: 10.1002/jso.23635] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
312 Yabusaki N, Yamada S, Murai T, Kanda M, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Sugimoto H, Koike M. Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Mol Clin Oncol. 2015;3:435-441. [PMID: 25798282 DOI: 10.3892/mco.2014.462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
313 Shi H, Ji M, Wu J, Zhou Q, Li X, Li Z, Zheng X, Xu B, Zhao W, Wu C. Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J Surg Oncol. 2014;12:188. [PMID: 24947047 DOI: 10.1186/1477-7819-12-188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
314 Zhou ML, Wang L, Wang JZ, Yang W, Hu R, Li GC, Sheng WQ, Zhang Z. Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection. Oncotarget 2016;7:64757-65. [PMID: 27588465 DOI: 10.18632/oncotarget.11665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
315 Choi YY, Lee JE, Kim H, Sim MH, Kim KK, Lee G, Kim HI, An JY, Hyung WJ, Kim CB, Noh SH, Kim S, Cheong JH. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 2016;6:22172. [PMID: 26926953 DOI: 10.1038/srep22172] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 10.2] [Reference Citation Analysis]
316 Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer 2017;20:92-101. [PMID: 27718136 DOI: 10.1007/s10120-016-0655-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
317 Ohkura Y, Shinohara H, Haruta S, Ueno M, Hashimoto M, Sakai Y, Udagawa H. Hepatectomy Offers Superior Survival Compared with Non-surgical Treatment for ≤ 3 Metastatic Tumors with Diameters < 3 cm from Gastric Cancer: A Retrospective Study. World J Surg 2015;39:2757-63. [PMID: 26148522 DOI: 10.1007/s00268-015-3151-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
318 Tan E, Lam S, Han SP, Storey D, Sandroussi C. Perioperative outcomes and survival in elderly patients aged ≥ 75 years undergoing gastrectomy for gastric cancer: an 18-year retrospective analysis in a single Western centre. Langenbecks Arch Surg 2021;406:1057-69. [PMID: 33770264 DOI: 10.1007/s00423-021-02116-w] [Reference Citation Analysis]
319 Li Z, Wu X, Gao X, Shan F, Ying X, Zhang Y, Ji J. Development and validation of an artificial neural network prognostic model after gastrectomy for gastric carcinoma: An international multicenter cohort study. Cancer Med. 2020;9:6205-6215. [PMID: 32666682 DOI: 10.1002/cam4.3245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
320 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
321 Lin JX, Wang ZK, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng HL, Zheng CH, Huang CM, Li P. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study. Ann Surg Oncol 2021. [PMID: 33768400 DOI: 10.1245/s10434-021-09830-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Liu J, Wei Y, Li S, Li Y, Liu H, Liu J, Zhu X. MicroRNA-744 promotes cell apoptosis via targeting B cell lymphoma-2 in gastric cancer cell line SGC-7901. Exp Ther Med 2018;16:3611-6. [PMID: 30233716 DOI: 10.3892/etm.2018.6602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
323 Merrett ND. Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects. World J Gastroenterol 2014; 20(36): 12892-12899 [PMID: 25278686 DOI: 10.3748/wjg.v20.i36.12892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
324 Zhang K, Lu C, Huang X, Cui J, Li J, Gao Y, Liang W, Liu Y, Sun Y, Liu H, Wei B, Chen L. Long noncoding RNA AOC4P regulates tumor cell proliferation and invasion by epithelial-mesenchymal transition in gastric cancer. Therap Adv Gastroenterol 2019;12:1756284819827697. [PMID: 30815034 DOI: 10.1177/1756284819827697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
325 Li Y, Zhu Z, Ma F, Xue L, Tian Y. Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy. Cancer Med 2020;9:6617-28. [PMID: 32744431 DOI: 10.1002/cam4.3342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
326 D'Ugo D, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates Surg 2020;72:355-78. [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Cho CS. Adjuvant Chemotherapy: What's the Rush? Ann Surg Oncol 2016;23:4130-3. [PMID: 27469122 DOI: 10.1245/s10434-016-5469-8] [Reference Citation Analysis]
328 Weltman E, Marta G, Baraldi H, Pimentel L, Castilho M, Maia M, Lundgren M, Chen M, Novaes P, Gadia R, Ferrigno R, Motta R, Hanna S, Almeida W. Treatment of abdominal tumors using radiotherapy. Rev Assoc Med Bras 2015;61:108-13. [DOI: 10.1590/1806-9282.61.02.108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
329 Goodman KA, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM, Thomas CR Jr. Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. Int J Radiat Oncol Biol Phys 2013;85:355-62. [PMID: 23040221 DOI: 10.1016/j.ijrobp.2012.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
330 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Reference Citation Analysis]
331 Zhou YJ, Lu XF, Meng JL, Wang XY, Zhang QW, Chen JN, Wang QW, Yan FR, Li XB. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis. BMC Cancer 2021;21:771. [PMID: 34217249 DOI: 10.1186/s12885-021-08534-9] [Reference Citation Analysis]
332 Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581. [PMID: 21431408 DOI: 10.1245/s10434-011-1631-5] [Cited by in Crossref: 334] [Cited by in F6Publishing: 311] [Article Influence: 30.4] [Reference Citation Analysis]
333 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
334 Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C, Park I, Park YS, Oh ST, Yook JH, Kim BS, Kang YK. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer 2016;19:226-33. [PMID: 25614467 DOI: 10.1007/s10120-015-0464-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
335 Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 2011;3:257-66. [PMID: 21792334 DOI: 10.2147/CMR.S12713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
336 Cañones Castelló ME. [Case report: a gastrectomized patient under treatment with chemotherapy and radiotherapy]. Enferm Clin 2008;18:216-9. [PMID: 18724920 DOI: 10.1016/s1130-8621(08)72199-5] [Reference Citation Analysis]
337 Benevento I, Bulzonetti N, De Felice F, Musio D, Vergine M, Tombolini V. The role of different adjuvant therapies in locally advanced gastric adenocarcinoma. Oncotarget 2018;9:34022-9. [PMID: 30338043 DOI: 10.18632/oncotarget.26106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
338 Zhang A, Deek MP, Kim S, Sayan M, Grann A, Wagman RT, Malhotra U, Hathout L, Biswal N, Zhang Y, Langenfeld J, Kennedy T, August DA, Jabbour SK. Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity. J Gastrointest Oncol 2019;10:513-22. [PMID: 31183202 DOI: 10.21037/jgo.2019.01.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
339 Turgeon MK, Gamboa AC, Rupji M, Lee RM, Switchenko JM, El-Rayes BF, Russell MC, Cardona K, Kooby DA, Staley CA, Maithel SK, Shah MM. Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer? Ann Surg Oncol 2021;28:97-105. [PMID: 32524459 DOI: 10.1245/s10434-020-08714-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Kang YK, Yoo C. Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. Am Soc Clin Oncol Educ Book 2012;:e31-4. [PMID: 24451826 DOI: 10.14694/EdBook_AM.2012.32.17] [Reference Citation Analysis]
341 Barreto SG, Windsor JA. Redefining early gastric cancer. Surg Endosc. 2015;Epub ahead of print. [PMID: 25829068 DOI: 10.1007/s00464-015-4184-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
342 Kaydıhan N, Çepni K, Ergen ŞA, Şenocak MŞ, Öksüz DÇ. Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy. Jpn J Radiol 2017;35:733-9. [PMID: 29064001 DOI: 10.1007/s11604-017-0692-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
343 Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF, Zhang XG. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010; 16(48): 6155-6162 [PMID: 21182234 DOI: 10.3748/wjg.v16.i48.6155] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
344 Gong W, Zhao H, Liu S, Guan J, Liu X, Hou Q, Zhu Z, Guo H. Outcomes of radiation therapy for resectable M0 gastric cancer. Oncotarget 2018;9:1726-34. [PMID: 29416726 DOI: 10.18632/oncotarget.22574] [Reference Citation Analysis]
345 Zarean E, Amini P, Yaseri M, Hajihosseini M, Azimi T, Mahmoudi M. Determining Risk Factors for Gastric and Esophageal Cancers between 2009-2015 in East-Azarbayjan, Iran Using Parametric Survival Models. Asian Pac J Cancer Prev 2019;20:443-9. [PMID: 30803206 DOI: 10.31557/APJCP.2019.20.2.443] [Reference Citation Analysis]
346 Koelzer VH, Langer R, Zlobec I, Lugli A. Tumor budding in upper gastrointestinal carcinomas. Front Oncol 2014;4:216. [PMID: 25177546 DOI: 10.3389/fonc.2014.00216] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
347 Che K, Zhao Y, Qu X, Pang Z, Ni Y, Zhang T, Du J, Shen H. Prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma. Onco Targets Ther. 2017;10:1039-1047. [PMID: 28255247 DOI: 10.2147/ott.s127762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
348 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
349 Menges M, Hoehler T. Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 2009;135:29-38. [PMID: 18523800 DOI: 10.1007/s00432-008-0425-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
350 Shi L, Wu C, Wu J, Zhou W, Ji M, Zhang H, Zhao J, Huang Y, Pei H, Li Z, Ju J, Jiang J. Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer. Radiat Oncol 2012;7:114. [PMID: 22827960 DOI: 10.1186/1748-717X-7-114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
351 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
352 Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008;68:299-317. [PMID: 18257608 DOI: 10.2165/00003495-200868030-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
353 Song T, Chen P, Fang M, Zhang X, Du D, Wu S. The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2020;12:1631-9. [PMID: 32184666 DOI: 10.2147/CMAR.S232930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
354 Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 2021;28:758-65. [PMID: 32696305 DOI: 10.1245/s10434-020-08864-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
355 Topal B, Demey K, Topal H, Jaekers J, Van Cutsem E, Vandecaveye V, Sagaert X, Prenen H. Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial. BMC Cancer 2017;17:771. [PMID: 29149865 DOI: 10.1186/s12885-017-3730-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
356 Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315 [PMID: 23745033 DOI: 10.3748/wjg.v19.i21.3309] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
357 Kim Y, Squires MH, Poultsides GA, Fields RC, Weber SM, Votanopoulos KI, Kooby DA, Worhunsky DJ, Jin LX, Hawkins WG, Acher AW, Cho CS, Saunders N, Levine EA, Schmidt CR, Maithel SK, Pawlik TM. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery 2017;162:285-94. [PMID: 28578142 DOI: 10.1016/j.surg.2017.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
358 Sura K, Ye H, Vu CC, Robertson JM, Kabolizadeh P. How many lymph nodes are enough?-defining the extent of lymph node dissection in stage I-III gastric cancer using the National Cancer Database. J Gastrointest Oncol 2018;9:1168-75. [PMID: 30603138 DOI: 10.21037/jgo.2018.09.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
359 Wan Z, Huang Z, Chen L. Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study. PLoS One 2017;12:e0181845. [PMID: 28746362 DOI: 10.1371/journal.pone.0181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
360 Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One 2012;7:e43236. [PMID: 22905237 DOI: 10.1371/journal.pone.0043236] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
361 Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. [PMID: 30789792 DOI: 10.1259/bjr.20181044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
362 Kung CH, Jestin Hannan C, Linder G, Johansson J, Nilsson M, Hedberg J, Lindblad M. Impact of surgical resection rate on survival in gastric cancer: nationwide study. BJS Open 2021;5:zraa017. [PMID: 33688944 DOI: 10.1093/bjsopen/zraa017] [Reference Citation Analysis]
363 Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981-90. [PMID: 20087786 DOI: 10.1245/s10434-009-0743-7] [Cited by in Crossref: 180] [Cited by in F6Publishing: 157] [Article Influence: 15.0] [Reference Citation Analysis]
364 Kubota T, Weisenthal L. Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer. 2006;9:82-87. [PMID: 16767362 DOI: 10.1007/s10120-006-0366-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
365 Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-33. [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136] [Cited by in Crossref: 466] [Cited by in F6Publishing: 253] [Article Influence: 46.6] [Reference Citation Analysis]
366 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
367 Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, Ham IH, Han SU. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013;42:44-54. [PMID: 23135628 DOI: 10.3892/ijo.2012.1687] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 8.0] [Reference Citation Analysis]
368 Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15(35): 4415-4422 [PMID: 19764093 DOI: 10.3748/wjg.15.4415] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
369 Xu W, Beeharry MK, Liu W, Yan M, Zhu Z. Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine. Biomed Res Int 2016;2016:3923585. [PMID: 28105420 DOI: 10.1155/2016/3923585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
370 Park DJ, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, Suh YS, Lee HS, Yang HK, Kim HH, Yoon SS. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1508-15. [PMID: 26259755 DOI: 10.1245/s10434-015-4790-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
371 Moretones C, León D, Navarro A, Santacruz O, Boladeras AM, Macià M, Cambray M, Navarro V, Modolell I, Guedea F. Interobserver variability in target volume delineation in postoperative radiochemotherapy for gastric cancer. A pilot prospective study. Clin Transl Oncol 2012;14:132-7. [PMID: 22301402 DOI: 10.1007/s12094-012-0772-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
372 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
373 Jiang DM, Suzuki C, Espin-Garcia O, Lim CH, Ma LX, Sun P, Sim HW, Natori A, Chan BA, Moignard S, Chen EX, Liu G, Swallow CJ, Darling GE, Wong R, Jang RW, Elimova E. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. Cancer Med 2020;9:3023-32. [PMID: 32130793 DOI: 10.1002/cam4.2948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
374 Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008; 14(20): 3165-3173 [PMID: 18506920 DOI: 10.3748/wjg.14.3165] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
375 Xu S, Feng L, Chen Y, Sun Y, Lu Y, Huang S, Fu Y, Zheng R, Zhang Y, Zhang R. Consistency mapping of 16 lymph node stations in gastric cancer by CT-based vessel-guided delineation of 255 patients. Oncotarget 2017;8:41465-73. [PMID: 28611300 DOI: 10.18632/oncotarget.18407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
376 Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761. [PMID: 23524864 DOI: 10.1093/an-nonc/mdt106] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
377 Maduekwe UN, Yoon SS. An evidence-based review of the surgical treatment of gastric adenocarcinoma. J Gastrointest Surg 2011;15:730-41. [PMID: 21399886 DOI: 10.1007/s11605-011-1477-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
378 Yura M, Takahashi T, Fukuda K, Nakamura R, Wada N, Fukada J, Kawakubo H, Takeuchi H, Shigematsu N, Kitagawa Y. A Highly Advanced Gastric Cancer Maintaining a Clinical Complete Response after Chemoradiotherapy Comprising S-1 and Cisplatin. Case Rep Gastroenterol 2018;12:578-85. [PMID: 30323733 DOI: 10.1159/000492206] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
379 Shin K, Park SJ, Lee J, Park CH, Song KY, Lee HH, Seo HS, Jung YJ, Park JM, Lee SH, Roh SY, Kim IH. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage. BMC Cancer 2019;19:1232. [PMID: 31852475 DOI: 10.1186/s12885-019-6433-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
380 Salem A, Hashem S, Mula-Hussain LY, Mohammed I, Nour A, Shelpai W, Daoud F, Morcos B, Yamin Y, Jaradat I, Khader J, Almousa A. Management strategies for locoregional recurrence in early-stage gastric cancer: retrospective analysis and comprehensive literature review. J Gastrointest Cancer 2012;43:77-82. [PMID: 20835925 DOI: 10.1007/s12029-010-9207-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
381 Chen QY, Lin GT, Zhong Q, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Huang CM. Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance. Gastric Cancer 2020;23:184-94. [PMID: 31300914 DOI: 10.1007/s10120-019-00986-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
382 Agolli L, Nicosia L. Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? World J Gastrointest Oncol 2018; 10(9): 271-281 [PMID: 30254722 DOI: 10.4251/wjgo.v10.i9.271] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
383 Isa N. Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother. 2014;19:259-266. [PMID: 25061519 DOI: 10.1016/j.rpor.2013.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
384 Yu C, Yu R, Zhu W, Song Y, Li T. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol 2012;138:255-9. [DOI: 10.1007/s00432-011-1085-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
385 Gamboa AC, Winer JH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.Cancers (Basel). 2019;11:1662. [PMID: 31717799 DOI: 10.3390/cancers11111662] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
386 Huang YY, Yang Q, Zhou SW, Wei Y, Chen YX, Xie DR, Zhang B. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis. PLoS One. 2013;8:e68939. [PMID: 23874819 DOI: 10.1371/journal.pone.0068939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
387 Li J, Huang Q, Zeng F, Li W, He Z, Chen W, Zhu W, Zhang B. The prognostic value of global DNA hypomethylation in cancer: a meta-analysis. PLoS One. 2014;9:e106290. [PMID: 25184628 DOI: 10.1371/journal.pone.0106290] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
388 Su Y, Lin L, Zhang J, Jiang Y, Pan C, Sun L, Duan J, Liao W. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Mol Med Rep 2015;12:5771-9. [PMID: 26239822 DOI: 10.3892/mmr.2015.4173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
389 Wang MJ, Li C, Sun Y, Shen FJ, Wang CB. Prognostic effect of adjuvant chemoradiotherapy for patients with gastric cancer: an updated evidence of randomized controlled trials. Oncotarget 2017;8:102880-7. [PMID: 29262530 DOI: 10.18632/oncotarget.21983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
390 Zhao Q, Li Y, Tan B, Fan L, Yang P, Tian Y, Cheng JQ. HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. PLoS ONE 2015;10:e0132746. [DOI: 10.1371/journal.pone.0132746] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
391 Ryan P, Furlong H, Murphy CG, O'Sullivan F, Walsh TN, Shanahan F, O'Sullivan GC. Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10-year follow-up confirms prognostic significance. Cancer Med 2015;4:1281-8. [PMID: 25914238 DOI: 10.1002/cam4.470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
392 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
393 Ge L, Wang HJ, Yin D, Lei C, Zhu JF, Cai XH, Zhang GQ. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: A meta-analysis. World J Gastroenterol 2012; 18(48): 7384-7393 [PMID: 23326149 DOI: 10.3748/wjg.v18.i48.7384] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
394 Rim CH, Shin IS, Lee HY, Yoon WS, Park S. Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review. Cancers (Basel) 2020;12:E2125. [PMID: 32751879 DOI: 10.3390/cancers12082125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
395 Ning ZK, Hu CG, Huang C, Liu J, Zhou TC, Zong Z. Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer. Front Oncol 2020;10:626912. [PMID: 33816214 DOI: 10.3389/fonc.2020.626912] [Reference Citation Analysis]
396 Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat 2018;4:18. [PMID: 34113719 DOI: 10.20517/2394-4722.2017.74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
397 Fukagawa T, Sasako M, Ito S, Nakanishi H, Iinuma H, Natsugoe S, Katai H, Shimoda T. The prognostic significance of isolated tumor cells in the lymph nodes of gastric cancer patients. Gastric Cancer 2010;13:191-6. [PMID: 20820989 DOI: 10.1007/s10120-010-0556-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
398 Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355-61. [PMID: 26779372 DOI: 10.7497/j.issn.2095-3941.2015.0054] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
399 Zhang YX, Yang K. Significance of nodal dissection and nodal positivity in gastric cancer. Transl Gastroenterol Hepatol 2020;5:17. [PMID: 32258521 DOI: 10.21037/tgh.2019.09.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
400 Vita FD, Martino ND, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: The role of new molecular drugs. World J Gastroenterol 2014; 20(40): 14537-14558 [PMID: 25356019 DOI: 10.3748/wjg.v20.i40.14537] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
401 Lee JM, Kim SS, Cho YS. The Role of PPARγ in Helicobacter pylori Infection and Gastric Carcinogenesis. PPAR Res 2012;2012:687570. [PMID: 22936949 DOI: 10.1155/2012/687570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
402 Oechsle K, Bokemeyer C, Hartmann JT, Budach W, Trarbach T, Stahl M, Boehlke I, Kollmannsberger C; German AIO/ARO/CAO group. Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. J Cancer Res Clin Oncol 2009;135:163-72. [PMID: 18825411 DOI: 10.1007/s00432-008-0463-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
403 Okuyama T, Korenaga D, Edagawa A, Itoh S, Oki E, Kawanaka H, Ikeda Y, Kakeji Y, Tateishi M, Tsujitani S. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surg Today. 2012;42:734-740. [PMID: 22278622 DOI: 10.1007/s00595-012-0129-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
404 Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol 2012;9:194-5. [PMID: 22392288 DOI: 10.1038/nrgastro.2012.35] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
405 Sun Z, Shenoi MM, Nussbaum DP, Keenan JE, Gulack BC, Tyler DS, Speicher PJ, Blazer DG 3rd. Feeding jejunostomy tube placement during resection of gastric cancers. J Surg Res 2016;200:189-94. [PMID: 26248478 DOI: 10.1016/j.jss.2015.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
406 Egawa N, Tanaka T, Matsufuji S, Yamada K, Ito K, Kitagawa H, Okuyama K, Kitajima Y, Noshiro H. Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1α-expressing gastric cancer cells. FEBS Open Bio 2021;11:1465-75. [PMID: 33773069 DOI: 10.1002/2211-5463.13154] [Reference Citation Analysis]
407 Lawrence W. Gastric Adenocarcinoma. Curr Treat Options Gastroenterol 2004;7:149-57. [PMID: 15010029 DOI: 10.1007/s11938-004-0036-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
408 Kundel Y, Purim O, Idelevich E, Lavrenkov K, Man S, Kovel S, Karminsky N, Pfeffer RM, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? a retrospective multi-institutional study. Radiat Oncol 2011;6:127. [PMID: 21958692 DOI: 10.1186/1748-717X-6-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
409 Fu J, Wang CY, Wang CG, Li HL, Yang XJ, Sun Y, Shao YH, Zhang LH, Yang XM, Zhang XL. Efficacy and Side Effects of Combined Capecitabine Plus Intensity Modulated Radiotherapy as an Effective Adjuvant Therapy for Gastric Cancers. Iran J Pharm Res 2020;19:365-71. [PMID: 33841549 DOI: 10.22037/ijpr.2019.14622.12542] [Reference Citation Analysis]
410 Kassam Z, Mackay H, Buckley CA, Fung S, Pintile M, Oza A, Brierley J, Swallow C, Cummings B, Knox JJ, Kim J, Wong R, Siu L, Feld R, Ringash J. Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study. Curr Oncol 2010;17:34-41. [PMID: 20697512 DOI: 10.3747/co.v17i4.521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
411 Ustaalioğlu BBÖ, Tilki M, Sürmelioğlu A, Bilici A, Gönen C, Ustaalioğlu R, Balvan Ö, Aliustaoğlu M. The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification. Turk J Surg 2017;33:18-24. [PMID: 28589183 DOI: 10.5152/UCD.2017.3379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
412 Luo W, Zhang H, Zhao Y, Wang L, Qi L, Ran J, Liu L, Wu A. A retrospective study on intensity-modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. Mol Clin Oncol 2016;4:740-8. [PMID: 27123273 DOI: 10.3892/mco.2016.804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
413 Shui L, Ren H, Yang X, Li J, Chen Z, Yi C, Zhu H, Shui P. The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. Front Oncol 2020;10:570465. [PMID: 33575207 DOI: 10.3389/fonc.2020.570465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
414 Helyer LK, O'Brien C, Coburn NG, Swallow CJ. Surgeons' knowledge of quality indicators for gastric cancer surgery. Gastric Cancer 2007;10:205-14. [PMID: 18095075 DOI: 10.1007/s10120-007-0435-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
415 Scartozzi M, Galizia E, Graziano F, Catalano V, Berardi R, Baldelli AM, Testa E, Mari D, Silva RR, Cascinu S. Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer 2005;92:1051-4. [PMID: 15770210 DOI: 10.1038/sj.bjc.6602468] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
416 Costa LB, Toneto MG, Moreira LF. DO PROXIMAL AND DISTAL GASTRIC TUMOURS BEHAVE DIFFERENTLY? Arq Bras Cir Dig 2016;29:232-5. [PMID: 28076476 DOI: 10.1590/0102-6720201600040005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
417 Reddy D, Wainberg ZA. Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol 2011;12:46-60. [PMID: 21298375 DOI: 10.1007/s11864-011-0138-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
418 Warschkow R, Baechtold M, Leung K, Schmied BM, Nussbaum DP, Gloor B, Blazer Iii DG, Worni M. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. Gastric Cancer. 2018;21:324-337. [PMID: 28646258 DOI: 10.1007/s10120-017-0742-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
419 Miceli R, Tomasello G, Bregni G, Bartolomeo MD, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World J Gastroenterol 2014; 20(16): 4516-4525 [PMID: 24782604 DOI: 10.3748/wjg.v20.i16.4516] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
420 Wu H, Qiao F, Zhao Y, Wu S, Hu M, Wu T, Huang F, Chen W, Sun D, Liu M, Zhao J. Downregulation of Long Non-coding RNA FALEC Inhibits Gastric Cancer Cell Migration and Invasion Through Impairing ECM1 Expression by Exerting Its Enhancer-Like Function. Front Genet 2019;10:255. [PMID: 30984243 DOI: 10.3389/fgene.2019.00255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
421 Yu WW, Guo YM, Zhang Q, Fu S. Benefits from adjuvant intraoperative radiotherapy treatment for gastric cancer: A meta-analysis. Mol Clin Oncol 2015;3:185-9. [PMID: 25469292 DOI: 10.3892/mco.2014.444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
422 Thuss-Patience P, Vecchione L, Keilholz U. Should cT2 esophageal cancer get neoadjuvant treatment before surgery? J Thorac Dis 2017;9:2819-23. [PMID: 29221247 DOI: 10.21037/jtd.2017.08.143] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
423 Lacueva FJ, Oliver I. Perioperative and adjuvant treatments for gastric cancer. Definitive new standards of care or are we still on the way? Clin Transl Oncol 2007;9:747-8. [PMID: 18158976 DOI: 10.1007/s12094-007-0134-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
424 Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, Chopitea A, Iragorri Y, Martínez-Regueira F, Ponz-Sarvise M, Arbea L, Subtil JC, Cano D, Ceniceros L, Legaspi J, Hernandez JL, Rodríguez J. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer 2016;115:655-63. [PMID: 27537382 DOI: 10.1038/bjc.2016.252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
425 He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 2014; 20(1): 264-273 [PMID: 24415881 DOI: 10.3748/wjg.v20.i1.264] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
426 Kelly MD, Walsh TN. Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ J Surg 2003;73:976-8. [PMID: 14632885 DOI: 10.1046/j.1445-2197.2003.t01-20-.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
427 Chang KK, Patel MS, Yoon SS. Linear-Stapled Side-to-Side Esophagojejunostomy with Hand-Sewn Closure of the Common Enterotomy After Prophylactic and Therapeutic Total Gastrectomy. J Gastrointest Surg 2017;21:712-22. [PMID: 27882512 DOI: 10.1007/s11605-016-3326-5] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
428 Hsieh CH, Hsieh YJ, Liu CY, Tai HC, Huang YC, Shueng PW, Wu LJ, Wang LY, Tsai TH, Chen YJ. Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics. J Transl Med 2010;8:29. [PMID: 20338060 DOI: 10.1186/1479-5876-8-29] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
429 Costa WL, Coimbra FJ, Ribeiro HS, Diniz AL, de Godoy AL, Begnami M, Silva MJ, Fanelli MF, Mello CA. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012;10:195. [PMID: 22992263 DOI: 10.1186/1477-7819-10-195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
430 Wilson KS. Postoperative chemoradiotherapy helps in gastric adenocarcinoma. BMJ. 2002;324:977. [PMID: 11964354 DOI: 10.1136/bmj.324.7343.977/a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
431 Puli SR, Reddy JBK, Bechtold ML, Antillon MR, Ibdah JA. How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review. World J Gastroenterol 2008; 14(25): 4011-4019 [PMID: 18609685 DOI: 10.3748/wjg.14.4011] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 70] [Article Influence: 6.5] [Reference Citation Analysis]
432 Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, Yuan XL, Liu TS, Li GX, Wu Q, Xu HM, Ji JF, Li YF, Wang X, Yu S, Liu H, Guan WL, Xu RH. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39:10. [PMID: 30885279 DOI: 10.1186/s40880-019-0349-9] [Cited by in Crossref: 123] [Cited by in F6Publishing: 120] [Article Influence: 41.0] [Reference Citation Analysis]
433 Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol. 2010;36:601-606. [PMID: 20126980 DOI: 10.3892/ijo_00000535] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
434 Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:1448-1455. [PMID: 24197761 DOI: 10.1245/s10434-013-3327-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
435 Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I. Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 2015;Epub ahead of print. [PMID: 25862567 DOI: 10.1007/s10120-015-0495-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
436 Ziogas D, Baltogiannis G, Fatouros M. Continuing debate on D2 lymphadenectomy for gastric cancer. World J Surg 2008;32:2127-8. [PMID: 18563483 DOI: 10.1007/s00268-008-9645-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Hadzitheodorou C, Moss RA, Kennedy TJ, Jabbour SK. Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series. Case Rep Oncol 2017;10:308-15. [PMID: 28512415 DOI: 10.1159/000464280] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
438 Yuan SQ, Wu WJ, Qiu MZ, Wang ZX, Yang LP, Jin Y, Yun JP, Gao YH, Li YH, Zhou ZW, Wang F, Xu RH. Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. J Cancer 2017;8:3498-505. [PMID: 29151934 DOI: 10.7150/jca.19879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
439 Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13:137-148. [PMID: 20820982 DOI: 10.1007/s10120-010-0560-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
440 Takabayashi K, Kashiwagi K, Kawata T, Sato T, Matsuoka K, Hisamatsu T, Takaishi H, Hibi T, Ogata H, Yahagi N, Kitagawa Y, Shigematsu N, Kanai T. Continuous low-dose irradiation by I-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin. Cancer Biol Ther 2014;15:81-8. [PMID: 24149371 DOI: 10.4161/cbt.26610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
441 Nomura E, Kayano H, Machida T, Izumi H, Yamamoto S, Sugawara A, Mukai M, Hasebe T. Neoadjuvant chemoradiotherapy for locally advanced gastric cancer with bulky lymph node metastasis: Five case reports. World J Clin Cases 2020; 8(18): 4177-4185 [PMID: 33024776 DOI: 10.12998/wjcc.v8.i18.4177] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Moningi S, Ajani JA, Badgwell BD, Murphy MB, Ikoma N, Mansfield PF, Ho JC, Suh Y, Crane C, Herman JM, Holliday EB, Koay E, Koong AC, Krishnan S, Minsky B, Smith G, Taniguchi C, Das P. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol 2020;5:369-76. [PMID: 32529130 DOI: 10.1016/j.adro.2019.11.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
443 Sudo K, Elimova E, Skinner HD, Hofstetter WL, Ajani JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol 2014;32:2112-3. [PMID: 24868018 DOI: 10.1200/JCO.2014.55.2331] [Reference Citation Analysis]
444 Spych M, Serbiak B, Rychter A, Jesien-Lewandowicz E, Gottwald L, Fijuth J. Post-operative radiochemotherapy in patients with gastric cancer: one department’s experience of 56 patients. Br J Radiol. 2011;84:457-463. [PMID: 21304007 DOI: 10.1259/bjr/25406515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
445 Tercioti-Junior V, Lopes LR, Sallum RA, Andreollo NA, Malafaia O. [Does adjuvant therapy associated with esophagectomy improve survival in patients with esophagogastric junction adenocarcinoma?]. Arq Bras Cir Dig 2013;26:77-9. [PMID: 24000015 DOI: 10.1590/s0102-67202013000200001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
446 Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, Liang J, Xu H. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526. [PMID: 23153379 DOI: 10.1186/1471-2407-12-526] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
447 Rajdev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol. 2010;11:14-23. [PMID: 20358316 DOI: 10.1007/s11864-010-0117-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
448 Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006; 12(20): 3237-3242 [PMID: 16718845 DOI: 10.3748/wjg.v12.i20.3237] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 74] [Article Influence: 4.9] [Reference Citation Analysis]
449 Xie ZS, Zhang XF, Liu GH, Liu T, Dong XH, Yang Z. Efficacy of docetaxel plus S-1 as neoadjuvant chemotherapy for operable advanced gastric cancer. Shijie Huaren Xiaohua Zazhi 2014; 22(34): 5334-5338 [DOI: 10.11569/wcjd.v22.i34.5334] [Reference Citation Analysis]
450 Pedrazzani C, Sivins A, Ancans G, Marrelli D, Corso G, Krumins V, Roviello F, Leja M. Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients. World J Surg. 2010;34:85-91. [PMID: 20020295 DOI: 10.1007/s00268-009-0288-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
451 Wang Y, Liu Z, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Front Oncol 2020;10:613988. [PMID: 33392098 DOI: 10.3389/fonc.2020.613988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
452 Pilar A, Gupta M, Ghosh Laskar S, Laskar S. Intraoperative radiotherapy: review of techniques and results. Ecancermedicalscience 2017;11:750. [PMID: 28717396 DOI: 10.3332/ecancer.2017.750] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
453 Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, Meunier B, Brigand C, Hamy A, Glehen O, Mariette C, Paye F. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027-1040. [PMID: 26606931 DOI: 10.1007/s10120-015-0564-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
454 Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002;4:213-21. [PMID: 11937011 DOI: 10.1007/s11912-002-0018-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
455 Hingorani DV, Crisp JL, Doan MK, Camargo MF, Quraishi MA, Aguilera J, Gilardi M, Gross LA, Jiang T, Li WT, Ongkeko WM, Cohen EEW, Gutkind JS, Adams SR, Advani SJ. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials 2020;248:120032. [PMID: 32304937 DOI: 10.1016/j.biomaterials.2020.120032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
456 Huang CY, Chen YM, Zhao JJ, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, Zhou ZW, Xia JC. Decreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One 2013;8:e54671. [PMID: 23372750 DOI: 10.1371/journal.pone.0054671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
457 Knight G, Earle CC, Cosby R, Coburn N, Youssef Y, Malthaner R, Wong RK; Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer. 2013;16:28-40. [PMID: 22467061 DOI: 10.1007/s10120-012-0148-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
458 Kim SY, Song X, Zhang L, Bartlett DL, Lee YJ. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochem Pharmacol. 2014;88:178-188. [PMID: 24486574 DOI: 10.1016/j.bcp.2014.01.027] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
459 Ning K, Shao Y, He Y, Wang F, Cui X, Liu F, Li D, Li F. Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3. Cancer Sci 2020;111:3679-92. [PMID: 32762126 DOI: 10.1111/cas.14594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
460 Khattak MA, Martin HL, Karapetis CS. Targeted therapy for esophagogastric cancers: a review. Onco Targets Ther 2012;5:91-102. [PMID: 22719211 DOI: 10.2147/OTT.S25117] [Reference Citation Analysis]
461 Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton GB, Saeger HD. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009;24:886-95. [PMID: 19655439 DOI: 10.1111/j.1440-1746.2008.05732.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
462 Tu CC, Huang CY, Cheng WL, Hung CS, Chang YJ, Wei PL. Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment. Tumour Biol 2016;37:9493-501. [PMID: 26790437 DOI: 10.1007/s13277-015-4751-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
463 Yang MH, Ha IJ, Um JY, Ahn KS. Albendazole Exhibits Anti-Neoplastic Actions against Gastric Cancer Cells by Affecting STAT3 and STAT5 Activation by Pleiotropic Mechanism(s). Biomedicines 2021;9:362. [PMID: 33807326 DOI: 10.3390/biomedicines9040362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
464 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
465 Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol 2015; 21(24): 7343-7348 [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
466 Cho J, Chang YH, Heo YJ, Kim S, Kim NK, Park JO, Kang WK, Lee J, Kim KM. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open. 2018;3:e000326. [PMID: 29636988 DOI: 10.1136/esmoopen-2018-000326] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
467 Hu P, Pan Y, Wang C, Zhang W, Huang H, Wang J, Zhang N. FLAD1 is up-regulated in Gastric Cancer and is a potential prediction of prognosis. Int J Med Sci 2020;17:1763-72. [PMID: 32714079 DOI: 10.7150/ijms.48162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
468 Li L, Li Y, Huang Y, Ouyang Y, Zhu Y, Wang Y, Guo X, Yuan Y, Gong K. Long non-coding RNA MIF-AS1 promotes gastric cancer cell proliferation and reduces apoptosis to upregulate NDUFA4. Cancer Sci 2018;109:3714-25. [PMID: 30238562 DOI: 10.1111/cas.13801] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
469 Martínez-Lago N, Vieito-Villar M, Vidal-Insua Y, Padin-Iruegas ME, Vazquez-Rivera F, Candamio-Folgar S, Lopez-Lopez R. Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. Clin Transl Oncol 2015;17:856-61. [PMID: 26133519 DOI: 10.1007/s12094-015-1314-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
470 Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol 2007;14:3290-2. [PMID: 17932722 DOI: 10.1245/s10434-007-9575-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
471 De B, Rhome R, Jairam V, Özbek U, Holcombe RF, Buckstein M, Ang C. Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer 2018;21:889-99. [PMID: 29691758 DOI: 10.1007/s10120-018-0826-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
472 Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 2017;8:81430-40. [PMID: 29113402 DOI: 10.18632/oncotarget.19226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
473 Thomson IG, Gotley DC, Barbour AP, Martin I, Jayasuria N, Thomas J, Smithers BM. Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer. 2014;17:152-160. [PMID: 23474836 DOI: 10.1007/s10120-013-0240-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
474 Tormo Ferrero V, Andreu Martínez FJ, Cardenal Macía R, Pomares Arias A. Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. Clin Transl Oncol 2006;8:611-5. [PMID: 16952851 DOI: 10.1007/s12094-006-0068-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
475 Wang F, Liu X, Mao P, Meng Q, Zhang D, Liu B. Relationship between the Body Mass Index and Tumor Site Postoperative Complications and Prognosis in Gastric Adenocarcinoma. The American Surgeon 2018;84:1861-8. [DOI: 10.1177/000313481808401229] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
476 Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017;35:3671-3677. [PMID: 28976791 DOI: 10.1200/jco.2017.74.2130] [Cited by in Crossref: 62] [Cited by in F6Publishing: 21] [Article Influence: 12.4] [Reference Citation Analysis]
477 Li Y, Zhu Z, Ma F, Xue L, Tian Y. Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges. Cancer Manag Res 2020;12:7973-81. [PMID: 32943931 DOI: 10.2147/CMAR.S268032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
478 Li GC, Zhang Z, Ma XJ, Gu WL, Wang YN, Li J. Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Mol Biol Rep. 2012;39:399-405. [PMID: 21559839 DOI: 10.1007/s11033-011-0751-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
479 Slagter AE, Vollebergh MA, Jansen EPM, van Sandick JW, Cats A, van Grieken NCT, Verheij M. Towards Personalization in the Curative Treatment of Gastric Cancer. Front Oncol. 2020;10:614907. [PMID: 33330111 DOI: 10.3389/fonc.2020.614907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
480 Nautiyal J, Kanwar SS, Majumdar AP. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. Curr Protein Pept Sci 2010;11:436-50. [PMID: 20491625 DOI: 10.2174/138920310791824110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
481 Koushyar S, Powell AG, Vincan E, Phesse TJ. Targeting Wnt Signaling for the Treatment of Gastric Cancer. Int J Mol Sci 2020;21:E3927. [PMID: 32486243 DOI: 10.3390/ijms21113927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
482 Tural D, Selçukbiricik F, Serdengeçti S, Büyükünal E. A comparison of patient characteristics, prognosis, treatment modalities, and survival according to age group in gastric cancer patients. World J Surg Oncol. 2012;10:234. [PMID: 23121731 DOI: 10.1186/1477-7819-10-234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
483 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
484 Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2008;88:43-50. [PMID: 18231723 DOI: 10.1007/s11060-008-9530-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
485 Sasako M. Surgery and adjuvant chemotherapy. Int J Clin Oncol. 2008;13:193-195. [PMID: 18553226 DOI: 10.1007/s10147-008-0791-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
486 Liu KT, Wan JF, Yu GH, Bei YP, Chen X, Lu MZ. The recommended treatment strategy for locally advanced gastric cancer in elderly patients aged 75 years and older: a Surveillance, Epidemiology, and End Results database analysis. J Cancer Res Clin Oncol 2017;143:313-20. [PMID: 27757528 DOI: 10.1007/s00432-016-2289-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
487 Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534-543. [PMID: 26487948 DOI: 10.3978/j.issn.2078-6891.2015.047] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
488 Smyth EC, Cunningham D. Targeted Therapy for Gastric Cancer. Curr Treat Options in Oncol 2012;13:377-89. [DOI: 10.1007/s11864-012-0192-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
489 Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer. 2002;86:1578-1585. [PMID: 12085207 DOI: 10.1038/sj.bjc.6600305] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
490 Chen XZ, Yang K, Liu J, Chen XL, Hu JK. Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer. World J Gastroenterol 2011; 17(40): 4542-4544 [PMID: 22110287 DOI: 10.3748/wjg.v17.i40.4542] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
491 Lee SJ, Do IG, Lee J, Kim KM, Jang J, Sohn I, Kang WK. Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013;8:271-280. [PMID: 23371028 DOI: 10.1007/s11523-013-0253-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
492 He Q, Zhao J, Yuan J, Gong Z, Yi T. Combined perioperative EOX chemotherapy and postoperative chemoradiotherapy for locally advanced gastric cancer. Mol Clin Oncol 2017;7:211-6. [PMID: 28781787 DOI: 10.3892/mco.2017.1300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
493 Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H, Tomita N, Kodaira T, Muro K. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015;14:37. [PMID: 26238344 DOI: 10.1186/s12904-015-0034-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
494 Jácome AA, Sankarankutty AK, dos Santos JS. Adjuvant therapy for gastric cancer: What have we learned since INT0116? World J Gastroenterol 2015; 21(13): 3850-3859 [PMID: 25852269 DOI: 10.3748/wjg.v21.i13.3850] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
495 Iwasa S, Yamada Y, Fukagawa T, Eguchi Nakajima T, Kato K, Hamaguchi T, Morita S, Saka M, Katai H, Shimada Y. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 2011;14:28-34. [PMID: 21327440 DOI: 10.1007/s10120-011-0003-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
496 Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij M. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329. [PMID: 21810227 DOI: 10.1186/1471-2047.11-329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
497 Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10-18. [PMID: 25861518 DOI: 10.5230/jgc.2015.15.1.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
498 Tseng J, Miller JP, Johnson J, Waters K, Gangi A, Gong J, Burch M. Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis. J Gastrointest Oncol 2021;12:1308-25. [PMID: 34532090 DOI: 10.21037/jgo-21-207] [Reference Citation Analysis]
499 Ye S, Wang L, Zuo Z, Bei Y, Liu K. The role of surgery and radiation in advanced gastric cancer: A population-based study of Surveillance, Epidemiology, and End Results database. PLoS One 2019;14:e0213596. [PMID: 30861056 DOI: 10.1371/journal.pone.0213596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
500 Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel). 2013;5:64-91. [PMID: 24216699 DOI: 10.3390/cancers5010064] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
501 Mao QQ, Xu XY, Shang A, Gan RY, Wu DT, Atanasov AG, Li HB. Phytochemicals for the Prevention and Treatment of Gastric Cancer: Effects and Mechanisms. Int J Mol Sci 2020;21:E570. [PMID: 31963129 DOI: 10.3390/ijms21020570] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
502 Eun H, Hur H, Byun CS, Son SY, Han SU, Cho YK. Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. J Gastric Cancer 2015;15:113-20. [PMID: 26161284 DOI: 10.5230/jgc.2015.15.2.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
503 Mrena J, Mattila A, Böhm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol 2015; 21(47): 13294-13301 [PMID: 26715812 DOI: 10.3748/wjg.v21.i47.13294] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
504 Cheng J, Squires MH 3rd, Mikell JL, Fisher SB, Staley CA 3rd, Kooby DA, El-Rayes BF, Curran WJ Jr, Hall WA, Colbert LE, Shelton JW, Maithel SK, Landry J, Yu DS. Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. J Gastrointest Oncol 2015;6:247-53. [PMID: 26029450 DOI: 10.3978/j.issn.2078-6891.2015.026] [Reference Citation Analysis]
505 Ni W, Yu S, Zhang W, Xiao Z, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Gao S, Mao Y, Xue Q, Sun K, Liu X, Fang D, Li J, Wang D. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. BMC Cancer 2020;20:130. [PMID: 32070309 DOI: 10.1186/s12885-020-6592-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
506 Sakuramoto S, Yamashita K, Kikuchi S, Futawatari N, Katada N, Watanabe M, Okutomi T, Wang G, Bax L. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surg Endosc 2013;27:1695-705. [PMID: 23247737 DOI: 10.1007/s00464-012-2658-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
507 Sun SS, Zhao AG, Yang JK, Zhao G, Cai Y, Li ZY. Effect of treatment with a Jianpi herbal formula on disease-free survival in patients with gastric cancer after radical gastrectomy. Shijie Huaren Xiaohua Zazhi 2011; 19(6): 581-587 [DOI: 10.11569/wcjd.v19.i6.581] [Reference Citation Analysis]
508 Diao F, Lai W, Chu Z. S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer. Cancer Commun (Lond) 2019;39:65. [PMID: 31655618 DOI: 10.1186/s40880-019-0408-2] [Reference Citation Analysis]
509 Zhu K, Diao D, Dang C, Shi L, Wang J, Yan R, Yuan D, Li K. Elevated KIAA0101 expression is a marker of recurrence in human gastric cancer. Cancer Sci 2013;104:353-9. [PMID: 23240630 DOI: 10.1111/cas.12083] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
510 Mabula JB, McHembe MD, Koy M, Chalya PL, Massaga F, Rambau PF, Masalu N, Jaka H. Gastric cancer at a university teaching hospital in northwestern Tanzania: a retrospective review of 232 cases. World J Surg Oncol. 2012;10:257. [PMID: 23181624 DOI: 10.1186/1477-7819-10-257] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
511 Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer. 2014;14:183. [PMID: 24628950 DOI: 10.1186/1471-2407-14-183] [Cited by in Crossref: 95] [Cited by in F6Publishing: 71] [Article Influence: 11.9] [Reference Citation Analysis]
512 Bhushan M, Yadav G, Tripathi D, Kumar L, Kishore V, Dewan A, Kumar G, Wahi IK, Gairola M. Dosimetric Analysis of Unflattened (FFFB) and Flattened (FB) Photon Beam Energy for Gastric Cancers Using IMRT and VMAT-a Comparative Study. J Gastrointest Cancer 2019;50:408-19. [PMID: 29520733 DOI: 10.1007/s12029-018-0080-9] [Reference Citation Analysis]
513 Lai YC, Yeh TS, Wu RC, Tsai CK, Yang LY, Lin G, Kuo MD. Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation. Cancers (Basel) 2019;11:E641. [PMID: 31075839 DOI: 10.3390/cancers11050641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
514 Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017;8:13320-13328. [PMID: 28076847 DOI: 10.18632/oncotarget.14519] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
515 Pereira MA, Ramos MFKP, Dias AR, Faraj SF, Cirqueira CDS, de Mello ES, Zilberstein B, Alves VAF, Ribeiro U Jr. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy. Chin J Cancer Res 2018;30:526-36. [PMID: 30510364 DOI: 10.21147/j.issn.1000-9604.2018.05.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
516 Choi AH, Nelson RA, Merchant SJ, Kim JY, Chao J, Kim J. Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populations. Gastrointest Endosc 2016;83:1184-1192.e1. [PMID: 26546980 DOI: 10.1016/j.gie.2015.10.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
517 Chang SC, Tang CM, Le PH, Kuo CJ, Chen TH, Wang SY, Chou WC, Chen TC, Yeh TS, Hsu JT. Impact of Pancreatic Resection on Survival in Locally Advanced Resectable Gastric Cancer. Cancers (Basel) 2021;13:1289. [PMID: 33799426 DOI: 10.3390/cancers13061289] [Reference Citation Analysis]
518 Khan MK, Syed AA, Khattak S, Kazmi SA, Yusuf A. Surgical management of gastric cancer: Single center experience from a developing country. South Asian J Cancer 2015;4:127-9. [PMID: 26942143 DOI: 10.4103/2278-330X.173169] [Reference Citation Analysis]
519 Li HW, Yang JK, Zhao AG. Adjuvant therapy for gastric cancer. Shijie Huaren Xiaohua Zazhi 2014; 22(32): 4921-4927 [DOI: 10.11569/wcjd.v22.i32.4921] [Reference Citation Analysis]
520 Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, Nakayama G, Koike M, Yamamura Y, Nakao A. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 2006;11:449-53. [PMID: 17180513 DOI: 10.1007/s10147-006-0618-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
521 Liu FF, Okunieff P, Bernhard EJ, Stone HB, Yoo S, Coleman CN, Vikram B, Brown M, Buatti J, Guha C; workshop participants. Lessons learned from radiation oncology clinical trials. Clin Cancer Res 2013;19:6089-100. [PMID: 24043463 DOI: 10.1158/1078-0432.CCR-13-1116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
522 Sun Y, Han C. Long Non-Coding RNA TMPO-AS1 Promotes Cell Migration and Invasion by Sponging miR-140-5p and Inducing SOX4-Mediated EMT in Gastric Cancer. Cancer Manag Res 2020;12:1261-8. [PMID: 32110100 DOI: 10.2147/CMAR.S235898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
523 Yin S, Wang P, Xu X, Tan Y, Huang J, Xu H. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. J Cancer. 2019;10:3094-3101. [PMID: 31289579 DOI: 10.7150/jca.30456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
524 Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11-21. [PMID: 23508452 DOI: 10.1007/s00595-013-0529-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
525 Girardi DM, de Lima MA, Pereira GCB, Negrão MV, López RVM, Capareli FC, Sabbaga J, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. BMC Cancer 2018;18:378. [PMID: 29614980 DOI: 10.1186/s12885-018-4305-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
526 Hawrylewicz L, Leszczyński W, Namysł-Kaletka A, Bronclik I, Wydmański J. Protection of organs at risk during neoadjuvant chemoradiotherapy for gastric cancer based on a comparison between conformal and intensity-modulated radiation therapy. Oncol Lett 2016;12:692-8. [PMID: 27347202 DOI: 10.3892/ol.2016.4633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
527 Kurokawa Y, Sasako M. The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer. Surg Oncol Clin N Am 2017;26:213-24. [PMID: 28279465 DOI: 10.1016/j.soc.2016.10.011] [Reference Citation Analysis]
528 Lei KF, Liu BY, Jin XL, Guo Y, Ye M, Zhu ZG. Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer. Exp Ther Med 2012;3:993-8. [PMID: 22970005 DOI: 10.3892/etm.2012.532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
529 Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y. Predictive Factors of Early Recurrence in Patients with Distal Cholangiocarcinoma after Pancreaticoduodenectomy. Gastroenterol Res Pract 2018;2018:6431254. [PMID: 29849596 DOI: 10.1155/2018/6431254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
530 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
531 Zhao B, Blair SL, Katz MHG, Lowy AM, Kelly KJ. Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer 2020;23:550-60. [PMID: 31745679 DOI: 10.1007/s10120-019-01028-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
532 Yamanaka N, Nagai E, Ohuchida K, Ueda J, Toma H, Shimizu S, Oda Y, Tanaka M. Feasibility of laparoscopic gastrectomy for advanced gastric cancer with positive peritoneal cytology. Surg Today 2013;43:859-64. [PMID: 22983736 DOI: 10.1007/s00595-012-0338-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
533 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
534 Huang SM, Chen YC, Chen WY, Yang LY, Tsan DL, Tsang NM, Yap WK, Tsai CS, Leung WM, Hong JH, Chang JT, Yeh TS, Wu TH, Chen YC, Lin YH, Huang BS. Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. J Cancer 2019;10:332-40. [PMID: 30719127 DOI: 10.7150/jca.27753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
535 Zheng Q, Zhao LY, Kong Y, Nan KJ, Yao Y, Liao ZJ. CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line. World J Surg Oncol. 2013;11:5. [PMID: 23311997 DOI: 10.1186/1477-7819-11-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
536 Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780 [PMID: 18609699 DOI: 10.3748/wjg.14.3773] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
537 Ahn HS, Sohn TS, Kim MJ, Cho BK, Kim SM, Kim ST, Yi EC, Lee C. SEPROGADIC - serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy. Sci Rep 2018;8:16892. [PMID: 30442939 DOI: 10.1038/s41598-018-34858-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
538 Zhu X, Li J. Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett 2010;1:407-12. [PMID: 22966316 DOI: 10.3892/ol_00000071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
539 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
540 Mahar AL, El-Sedfy A, Brar SS, Johnson A, Coburn N. Are we lacking economic evaluations in gastric cancer treatment? Pharmacoeconomics 2015;33:83-7. [PMID: 25192732 DOI: 10.1007/s40273-014-0215-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
541 Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT. Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg 2016;20:172-9; discussion 179. [PMID: 26394879 DOI: 10.1007/s11605-015-2954-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
542 Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020;12:1758835920930359. [PMID: 32754227 DOI: 10.1177/1758835920930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
543 Liu YY, Fang WL, Wang F, Hsu JT, Tsai CY, Liu KH, Yeh CN, Chen TC, Wu RC, Chiu CT, Yeh TS. Does a Higher Cutoff Value of Lymph Node Retrieval Substantially Improve Survival in Patients With Advanced Gastric Cancer?-Time to Embrace a New Digit. Oncologist 2017;22:97-106. [PMID: 27789777 DOI: 10.1634/theoncologist.2016-0239] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
544 Karagkounis G, Squires MH 3rd, Melis M, Poultsides GA, Worhunsky D, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Masi A, Berman R, Pachter HL, Staley CA, Newman E, Maithel SK, Hatzaras I. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. J Gastrointest Surg 2017;21:1984-92. [PMID: 28963709 DOI: 10.1007/s11605-017-3594-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
545 León-Espinoza C, López-Mozos F, Marti-Obiol R, Garces-Albir M, Ortega-Serrano J. “Magic” of our gastric cancer results on perioperative chemotherapy. World J Gastrointest Pathophysiol 2016; 7(3): 283-287 [PMID: 27574566 DOI: 10.4291/wjgp.v7.i3.283] [Reference Citation Analysis]
546 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
547 Murthy K, Shukeili K, Kumar S, Davis C, Chandran R, Namrata S. Evaluation of dose coverage to target volume and normal tissue sparing in the adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT. Biomed Imaging Interv J 2010;6:e29. [PMID: 21611046 DOI: 10.2349/biij.6.3.e29] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
548 Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012;53:248-57. [PMID: 22318810 DOI: 10.3349/ymj.2012.53.2.248] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
549 MacLellan SJ, MacKay HJ, Ringash J, Jacks L, Kassam Z, Conrad T, Khalili I, Okrainec A. Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection. Surg Endosc. 2012;26:1813-1821. [PMID: 22350227 DOI: 10.1007/s00464-011-2118-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
550 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 34.3] [Reference Citation Analysis]
551 Scartozzi M, Galizia E, Verdecchia L, Berardi R, Graziano F, Catalano V, Giordani P, Mari D, Silva RR, Marmorale C, Zingaretti C, Cascinu S. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer 2006;95:445-9. [PMID: 16880789 DOI: 10.1038/sj.bjc.6603286] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
552 Zhang Q, Jin XS, Yang ZY, Wei M, Zhu XC, Wang P, Liu BY, Gu QL. Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncol Lett 2013;5:896-902. [PMID: 23425977 DOI: 10.3892/ol.2012.1092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
553 Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002;4:222-228. [PMID: 11937012 DOI: 10.1007/s11912-002-0019-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
554 Pepek JM, Chino JP, Willett CG, Palta M, Blazer Iii DG, Tyler DS, Uronis HE, Czito BG. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013;8:6. [PMID: 23286735 DOI: 10.1186/1748-717X-8-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
555 Kim S, Kim JS, Jeong HY, Noh SM, Kim KW, Cho MJ. Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancer. Radiat Oncol J. 2011;29:252-259. [PMID: 22984678 DOI: 10.3857/roj.2011.29.4.252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
556 Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 2009;126:615-628. [PMID: 19657673 DOI: 10.1007/x00439-009-0722-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
557 Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. J Exp Clin Cancer Res. 2014;33:110. [PMID: 25528067 DOI: 10.1186/s13046-014-0110-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
558 Gotfrit J, Goodwin R, Asmis T, Hyde AJ, Alcindor T, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, Thirlwell M, Valdes M, Welch S, Vickers M. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. Curr Oncol 2021;28:1988-2006. [PMID: 34073199 DOI: 10.3390/curroncol28030185] [Reference Citation Analysis]
559 Schernberg A, Rivin Del Campo E, Rousseau B, Matzinger O, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol 2018;10:13-22. [PMID: 29928701 DOI: 10.1016/j.ctro.2018.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
560 Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:741-747. [PMID: 18164837 DOI: 10.1016/j.ijrobp.2007.10.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
561 Rausei S, Dionigi G, Rovera F, Boni L, Valerii C, Giavarini L, Frattini F, Dionigi R. A decade in gastric cancer curative surgery: Evidence of progress (1999-2009). World J Gastrointest Surg 2012; 4(3): 45-54 [PMID: 22530078 DOI: 10.4240/wjgs.v4.i3.45] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
562 Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N, Nishimura T. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol. 2011;137:125-130. [PMID: 20336314 DOI: 10.1007/s00432-010-0866-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
563 Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba MS, Morita S, Kono T, Tsuburaya A. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol 2014;73:1047-54. [PMID: 24652604 DOI: 10.1007/s00280-014-2440-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
564 Xu Y, Yu X, Chen Q, Mao W. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol 2012;10:173. [PMID: 22920951 DOI: 10.1186/1477-7819-10-173] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
565 Crisan A, Badulescu F, Badulescu A, Simionescu C, Andrei I, Cimpeanu R. Clinical, Histological and Prognosis Correlations in Diagnosis and Treatment of Gastric Cancer. Curr Health Sci J 2016;42:238-56. [PMID: 30581578 DOI: 10.12865/CHSJ.42.03.04] [Reference Citation Analysis]
566 Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 2012;17:346-58. [PMID: 22334453 DOI: 10.1634/theoncologist.2011-0311] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
567 Aichler M, Luber B, Lordick F, Walch A. Proteomic and metabolic prediction of response to therapy in gastric cancer. World J Gastroenterol 2014; 20(38): 13648-13657 [PMID: 25320503 DOI: 10.3748/wjg.v20.i38.13648] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
568 Gemici C, Yaprak G, Ozdemir S, Baysal T, Seseogullari OO, Ozyurt H. Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning. Radiat Oncol 2018;13:238. [PMID: 30509287 DOI: 10.1186/s13014-018-1189-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
569 Tetzlaff ED. Factors to consider before referring patients for major cancer surgery. JAAPA 2007;20:21-2, 24, 26 passim. [PMID: 17416020 DOI: 10.1097/01720610-200703000-00013] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
570 Liu HC, Hung SK, Huang CJ, Chen CC, Chen MJ, Chang CC, Tai CJ, Tzen CY, Lu LH, Chen YJ. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005; 11(34): 5367-5372 [PMID: 16149148 DOI: 10.3748/wjg.v11.i34.5367] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
571 Mansouri H, Zemni I, Achouri L, Mahjoub N, Ayedi MA, Ben Safta I, Ben Dhiab T, Chargui R, Rahal K. Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria? Rep Pract Oncol Radiother 2021;26:266-80. [PMID: 34211778 DOI: 10.5603/RPOR.a2021.0040] [Reference Citation Analysis]
572 Maduekwe UN, Lauwers GY, Fernandez-Del-Castillo C, Berger DL, Ferguson CM, Rattner DW, Yoon SS. New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol. 2010;17:1267-1277. [PMID: 20099040 DOI: 10.1245/s10434-010-0914-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
573 Shigaki H, Baba Y, Watanabe M, Murata A, Iwagami S, Miyake K, Ishimoto T, Iwatsuki M, Baba H. LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer 2013;16:480-7. [PMID: 23179365 DOI: 10.1007/s10120-012-0209-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
574 Sharfo AWM, Stieler F, Kupfer O, Heijmen BJM, Dirkx MLP, Breedveld S, Wenz F, Lohr F, Boda-Heggemann J, Buergy D. Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer. Radiat Oncol 2018;13:74. [PMID: 29685166 DOI: 10.1186/s13014-018-1032-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
575 Sereno M, De Castro J, Belda-Iniesta C, Garcia-Cabezas MA, Cejas P, Casado E, Barriuso J, Feliu J, Larrauri J. EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment. Pathol Oncol Res 2009;15:1-10. [PMID: 19002606 DOI: 10.1007/s12253-008-9118-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
576 Liu N, Molena D, Stem M, Blackford AL, Sewell DB, Lidor AO. Underutilization of Treatment for Regional Gastric Cancer Among the Elderly in the USA. J Gastrointest Surg 2018;22:955-63. [PMID: 29404983 DOI: 10.1007/s11605-018-3691-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
577 Cananzi FC, Biondi A, Quagliuolo V, Rausei S. Chemoradiotherapy in Gastric Cancer: A Door Ajar. J Clin Oncol 2016;34:1421-2. [PMID: 26811515 DOI: 10.1200/JCO.2015.60.9537] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
578 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
579 Zhang X, Kong Y, Xu X, Xing H, Zhang Y, Han F, Li W, Yang Q, Zeng J, Jia J. F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. Oncotarget. 2014;5:6178-6190. [PMID: 25115392 DOI: 10.18632/oncotarget.2183] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
580 He Q, Ma L, Li Y, Li G. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. BMC Gastroenterol. 2016;16:8. [PMID: 26782354 DOI: 10.1186/s12876-016-0422-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
581 Carcas LP. Gastric cancer review. J Carcinog. 2014;13:14. [PMID: 25589897 DOI: 10.4103/1477-3163.146506] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 15.8] [Reference Citation Analysis]
582 Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Transl Oncol 2015;8:288-94. [PMID: 26310375 DOI: 10.1016/j.tranon.2015.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
583 He X, Chen W, Tang D, Wen F, Zhang P, Li Q. Factors related to the receipt of adjuvant therapy among patients with gastric cancer in Western China. Eur J Cancer Care (Engl) 2019;28:e13012. [PMID: 30748055 DOI: 10.1111/ecc.13012] [Reference Citation Analysis]
584 Deng ZJ, Nie RC, Lu J, Chen XJ, Xiang J, Huang CM, Chen YB, Peng JS, Chen S. Survival analysis of stage II gastric cancer patients after D2 gastrectomy: a Chinese people-based research. BMC Gastroenterol 2021;21:363. [PMID: 34620108 DOI: 10.1186/s12876-021-01937-9] [Reference Citation Analysis]
585 Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, Germer CT, Pelz J, Kerscher AG. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73. [PMID: 25879885 DOI: 10.1186/s12885-015-1081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
586 Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag 2008;4:999-1007. [PMID: 19209281 DOI: 10.2147/tcrm.s3226] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
587 Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 2011;396:743-58. [PMID: 21234760 DOI: 10.1007/s00423-010-0738-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
588 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
589 Dudeja V, Habermann EB, Abraham A, Zhong W, Parsons HM, Tseng JF, Al-Refaie WB. Is there a role for surgery with adequate nodal evaluation alone in gastric adenocarcinoma? J Gastrointest Surg. 2012;16:238-246; discussion 246-247. [PMID: 22089951 DOI: 10.1007/s11605-011-1756-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
590 Cordero-García E, Ramos-Esquivel A, Alpízar-Alpízar W. Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study. J Gastrointest Oncol 2019;10:523-8. [PMID: 31183203 DOI: 10.21037/jgo.2019.01.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
591 van Amelsfoort RM, van der Sluis K, Schats W, Jansen EPM, van Sandick JW, Verheij M, Walraven I. Health-Related Quality of Life in Locally Advanced Gastric Cancer: A Systematic Review. Cancers (Basel) 2021;13:5934. [PMID: 34885043 DOI: 10.3390/cancers13235934] [Reference Citation Analysis]
592 Song XH, Zhang WH, Kai-Liu, Chen XL, Zhao LY, Chen XZ, Kun-Yang, Zhou ZG, Hu JK. Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China. World J Surg Oncol 2020;18:204. [PMID: 32792016 DOI: 10.1186/s12957-020-01987-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
593 Yaprak G, Gemici C, Temizkan S, Ozdemir S, Dogan BC, Seseogullari OO. Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer. BMC Cancer 2018;18:972. [PMID: 30309324 DOI: 10.1186/s12885-018-4899-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
594 Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, Hoff PMG, Ribeiro U Jr, Cecconello I. Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. J Gastrointest Surg. 2020;24:19-27. [PMID: 31745892 DOI: 10.1007/s11605-019-04462-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
595 Wang T, Chen Y, Zhao L, Zhou H, Wu C, Zhang X, Zhou A, Jin J, Zhao D. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. J Cancer 2021;12:379-86. [PMID: 33391434 DOI: 10.7150/jca.46847] [Reference Citation Analysis]
596 Luo H, Cui YY, Zhang JG, Sun YN, Zheng XL, Yang CL, Ye K, Ge H. Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma. Clin Transl Oncol 2018;20:889-98. [PMID: 29143229 DOI: 10.1007/s12094-017-1803-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
597 Koukourakis GV. Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer. World J Gastrointest Oncol 2011; 3(9): 131-136 [PMID: 22007277 DOI: 10.4251/wjgo.v3.i9.131] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
598 Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454-63. [PMID: 15120371 DOI: 10.1016/j.gassur.2003.12.014] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 5.3] [Reference Citation Analysis]
599 Ema A, Waraya M, Yamashita K, Kokubo K, Kobayashi H, Hoshi K, Shinkai Y, Kawamata H, Nakamura K, Nishimiya H, Katada N, Watanabe M. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. Cancer Med 2015;4:90-100. [PMID: 25154973 DOI: 10.1002/cam4.311] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
600 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
601 McNamara MJ, Adelstein DJ, Allende DS, Bodmann JW, Ives DI, Murthy SC, Raymond D, Raja S, Rodriguez CP, Sohal D, Stephans KL, Videtic GMM, Rybicki LA. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes. J Gastrointest Cancer 2017;48:181-9. [PMID: 27734205 DOI: 10.1007/s12029-016-9881-x] [Reference Citation Analysis]
602 Zhang S, Jiang XH. Neoadjuvant therapy in gastric cancer: Current status and future perspectives. Shijie Huaren Xiaohua Zazhi 2018; 26(33): 1939-1946 [DOI: 10.11569/wcjd.v26.i33.1939] [Reference Citation Analysis]
603 Ziogas D, Liakakos T. Lessons from laparoscopic gastrectomy: preventing surgical complications. Ann Surg Oncol 2008;15:2624-5. [PMID: 18461403 DOI: 10.1245/s10434-008-9939-5] [Reference Citation Analysis]
604 Ziogas D, Baltogiannis G, Fatouros M. Lymphadenectomy in surgical oncology. Ann Surg Oncol 2008;15:386-7; author reply 388-9. [PMID: 17909907 DOI: 10.1245/s10434-007-9617-z] [Reference Citation Analysis]
605 Meng C, Yin H, Sun Z, Zhou J, Chen S, Bai C, Zhao L. Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study. Transl Oncol 2014;7:277-83. [PMID: 24704535 DOI: 10.1016/j.tranon.2014.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
606 Jin Y, Qiu MZ, Wang DS, Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. PLoS One 2013;8:e53149. [PMID: 23359796 DOI: 10.1371/journal.pone.0053149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
607 Peng J, Wei Y, Zhou F, Dai J, Zhong Y, Xie C, Qin Y, Gong J, Xiong B, Zhou Y. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Med. 2016;5:2773-2780. [PMID: 27666138 DOI: 10.1002/cam4.873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
608 Pozzuto L, Silveira MN, Mendes MCS, Macedo LT, Costa FO, Martinez CAR, Coy CSR, da Cunha Júnior AD, Carvalheira JBC. Myosteatosis Differentially Affects the Prognosis of Non-Metastatic Colon and Rectal Cancer Patients: An Exploratory Study. Front Oncol 2021;11:762444. [PMID: 34858841 DOI: 10.3389/fonc.2021.762444] [Reference Citation Analysis]
609 Fujitani K, Tamura S, Kimura Y, Matsuyama J, Imamura H, Yamamoto K, Fujita J, Iijima S, Ueda S, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). Gastric Cancer. 2020;23:520-530. [PMID: 31667688 DOI: 10.1007/s10120-019-01023-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
610 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
611 Liakakos T, Xeropotamos N, Ziogas D, Roukos D. EGFR as a Prognostic Marker for Gastric Cancer. World J Surg. 2008;32:1225-1226; author reply 1227-1229. [PMID: 18224475 DOI: 10.1007/s00268- 007-9434-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
612 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
613 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco.2009.26.6114] [Cited by in Crossref: 387] [Cited by in F6Publishing: 204] [Article Influence: 32.3] [Reference Citation Analysis]
614 Hoang T, Dayyani F, Alfaro A, Huynh J, Ji J, Ko AH, Cho M, Hiyama D. Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. J Gastrointest Oncol 2020;11:952-63. [PMID: 33209490 DOI: 10.21037/jgo-20-212] [Reference Citation Analysis]
615 Bai H, Mei JZ, Li M, Xiao P. Efficacy of SOX regimen versus XELOX regimen in concurrent chemoradiotherapy for postoperative recurrent gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(12): 1720-1724 [DOI: 10.11569/wcjd.v22.i12.1720] [Reference Citation Analysis]
616 Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24. [PMID: 21617522 DOI: 10.1097/PAI.0b013e31821c821c] [Cited by in Crossref: 80] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
617 McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep. 2012;14:342-349. [PMID: 22544559 DOI: 10.1007/s11912-012-0239-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
618 Yang K, Hu JK. Gastric cancer treatment: similarity and difference between China and Korea. Transl Gastroenterol Hepatol 2017;2:36. [PMID: 28529990 DOI: 10.21037/tgh.2017.04.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
619 Ognjenovic L, Shumkovski A, Gjoshev S, Volchevski G, Trajkovski G, Karadzov Z, Dzambaz D, Hadzi-Manchev D, Hadzi-Manchev T, Petrushevska G, Janevska V, Janevski V, Brzanov N. EBV Positive Gastric Carcinomas and Their Clinicopathological Characteristics. Open Access Maced J Med Sci 2018;6:1829-32. [PMID: 30455757 DOI: 10.3889/oamjms.2018.409] [Reference Citation Analysis]
620 Chen ZM, Huang L, Li MM, Meng L, Ying SC, Xu AM. Inhibitory effects of isocryptotanshinone on gastric cancer. Sci Rep. 2018;8:9307. [PMID: 29915371 DOI: 10.1038/s41598-018-27638-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
621 Bickenbach K, Strong VE. Comparisons of Gastric Cancer Treatments: East vs. West. J Gastric Cancer. 2012;12:55-62. [PMID: 22792517 DOI: 10.5230/jgc.2012.12.2.55] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 8.0] [Reference Citation Analysis]
622 Unger JM, LeBlanc M, Blanke CD. The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. JAMA Oncol 2017;3:1345-51. [PMID: 28586789 DOI: 10.1001/jamaoncol.2017.0762] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
623 Ringash J, Smalley SR, Gunderson LL. Locoregional control remains a critical issue in gastric cancer. Gastric Cancer 2008;11:64-5. [PMID: 18373180 DOI: 10.1007/s10120-008-0454-y] [Reference Citation Analysis]
624 Conrad T, MacLellan S, Kassam Z, Mackay H, Khalili I, Sykes J, Purdie T, Okrainec A, Ringash J. Retrospective assessment of patterns of recurrence relative to radiotherapy volumes for adjuvant conformal chemoradiotherapy in gastric cancer. Gastric Cancer 2016;19:887-93. [PMID: 26362272 DOI: 10.1007/s10120-015-0534-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
625 Serarslan A, Ozbek Okumus N, Gursel B, Meydan D, Dastan Y, Aksu T. Dosimetric Comparison of Three Different Radiotherapy Techniques in Antrum-Located Stomach Cancer. Asian Pac J Cancer Prev 2017;18:741-6. [PMID: 28441708 DOI: 10.22034/APJCP.2017.18.3.741] [Reference Citation Analysis]
626 Chen X, Eads JR, Ammori JB, Kumar AM, Biswas T, Dorth JA. Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach? Curr Oncol Rep 2015;17:18. [PMID: 25708803 DOI: 10.1007/s11912-015-0442-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
627 Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006; 12(2): 204-213 [PMID: 16482619 DOI: 10.3748/wjg.v12.i2.204] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 58] [Article Influence: 3.7] [Reference Citation Analysis]
628 Dabak R, Uygur-Bayramicli O, Gemici C, Yavuzer D, Sargin M, Yildirim M. Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapy. World J Gastroenterol 2006; 12(27): 4411-4415 [PMID: 16865788 DOI: 10.3748/wjg.v12.i27.4411] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
629 Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, Wu ZJ, Cheng GJ, Wang F, Ni F, Wang XL, Cao GX, Huang J, Cai J. NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol 2014;35:6351-6. [PMID: 24664584 DOI: 10.1007/s13277-014-1839-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
630 Li GC, Zhang Z, Ma XJ, Yu XL, Hu WG, Wang JZ, Li QW, Liang LP, Shen LJ, Zhang H, Fan M. Variations in CT determination of target volume with active breath co-ordinate in radiotherapy for post-operative gastric cancer. Br J Radiol 2016;89:20150332. [PMID: 26654032 DOI: 10.1259/bjr.20150332] [Reference Citation Analysis]
631 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol 2016; 22(3): 1139-1159 [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
632 Wals A, Contreras J, Macías J, Fortes I, Rivas D, González P, Herruzo I. Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. Clin Transl Oncol 2006;8:271-8. [PMID: 16648103 DOI: 10.1007/BF02664938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
633 Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245:873-879. [PMID: 17522512 DOI: 10.1097/01.sla.0000254370.29893.e4] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 8.2] [Reference Citation Analysis]
634 Kang BW, Kim JG, Chae YS, Lee YJ, Lee SJ, Moon JH, Sohn SK, Jung MK, Jeon SW, Jang YJ, Seo J, Lee YH, Kwon O, Chung HY, Yu W. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs 2012;30:1671-5. [PMID: 21845514 DOI: 10.1007/s10637-011-9729-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
635 Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World J Gastrointest Oncol 2022; 14(1): 181-202 [DOI: 10.4251/wjgo.v14.i1.181] [Reference Citation Analysis]
636 Song XH, Liu K, Yang SJ, Zhang WH, Chen XL, Zhao LY, Chen XZ, Yang K, Zhou ZG, Hu JK. Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Front Oncol 2020;10:1432. [PMID: 33014781 DOI: 10.3389/fonc.2020.01432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
637 Zhou X, Chen H, Li S, Hua J, Zhang W, Li X, Si X, Zhang G. Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study. Cancer Control 2021;28:10732748211063955. [PMID: 34913741 DOI: 10.1177/10732748211063955] [Reference Citation Analysis]
638 Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, Kikuchi H, Kagaya T. Alternating treatment with S-1 plus low-dose cisplatin and S-1 alone for advanced gastric cancer. J Gastrointest Surg 2011;15:791-6. [PMID: 21512899 DOI: 10.1007/s11605-011-1476-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
639 Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist 2013;18:1013-21. [PMID: 23966224 DOI: 10.1634/theoncologist.2012-0462] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
640 Vošmik M, Laco J, Sirák I, Dvořák J, Lochman P, Hodek M, Malá P, Rejchrt S, Repák R, Leško M, Ferko A, Ryška A, Melichar B, Petera J. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery. Pathol Oncol Res 2018;24:373-83. [PMID: 28550507 DOI: 10.1007/s12253-017-0253-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
641 Zhai YJ, Su YP, Wang SJ, Ning FL, Wang ZB, Yu WZ, Chen SS. A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy. Oncol Lett 2014;8:1844-8. [PMID: 25202423 DOI: 10.3892/ol.2014.2382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
642 Wong RK, Jang R, Darling G. Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. J Gastrointest Oncol. 2015;6:89-107. [PMID: 25642342 DOI: 10.3978/j.issn.2078-6891.2014.089] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
643 Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006;243:74-81. [PMID: 16371739 DOI: 10.1097/01.sla.0000194088.81126.85] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
644 Khorfan R, Schlick CJR, Yang AD, Odell DD, Bentrem DJ, Merkow RP. Utilization of Minimally Invasive Surgery and Its Association with Chemotherapy for Locally Advanced Gastric Cancer. J Gastrointest Surg 2020;24:243-52. [PMID: 31749097 DOI: 10.1007/s11605-019-04410-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
645 Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun 2016;7:13019. [PMID: 27698471 DOI: 10.1038/ncomms13019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
646 Chan MM, Sjoquist KM, Zalcberg JR. Clinical utility of ramucirumab in advanced gastric cancer. Biologics 2015;9:93-105. [PMID: 26451083 DOI: 10.2147/BTT.S62777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
647 Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg. 2003;7:1015-1022; discussion 1023. [PMID: 14675711 DOI: 10.1016/j.gassur.2003.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
648 Rivera F, Carrato A, Grávalos C, Pericay C, Sastre J, Aranda E. Recommendations on current approach to gastric cancer. Clin Transl Oncol 2009;11:518-25. [PMID: 19661026 DOI: 10.1007/s12094-009-0396-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
649 Liu Y, Ling Y, Qi Q, Zhu M, Wan M, Zhang Y, Zhang C. Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. Oncol Lett 2015;9:999-1005. [PMID: 25624920 DOI: 10.3892/ol.2014.2793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
650 Byfield SA, Earle CC, Ayanian JZ, McCarthy EP. Treatment and outcomes of gastric cancer among United States-born and foreign-born Asians and Pacific Islanders. Cancer 2009;115:4595-605. [PMID: 19626648 DOI: 10.1002/cncr.24487] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
651 Lacueva J, Gallego J, Díaz-González JA. Updating controversies on the multidisciplinary management of gastric cancer. Clin Transl Oncol. 2010;12:677-685. [PMID: 20947482 DOI: 10.1007/s12094-010-0577-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
652 Morita S, Fukagawa T, Fujiwara H, Katai H. Questionnaire survey regarding the current status of super-extended lymph node dissection in Japan. World J Gastrointest Oncol 2016; 8(9): 707-714 [PMID: 27672429 DOI: 10.4251/wjgo.v8.i9.707] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
653 Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight 2016;1:e87607. [PMID: 27699276 DOI: 10.1172/jci.insight.87607] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
654 Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15. [PMID: 16722549 DOI: 10.1186/1748-717X-1-15] [Cited by in Crossref: 50] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
655 Fatouros M, Baltogiannis G. To the editor: the role of prophylactic surgery in cancer prevention. World J Surg 2008;32:1219-20; author reply 1221-2. [PMID: 18058170 DOI: 10.1007/s00268-007-9283-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
656 Li Y, Wang WB, Jiang HG, Dai J, Xia L, Chen J, Xie CH, Peng J, Liao ZK, Gao Y, Zhou YF, Zhou FX. Predictive value of pancreatic dose-volume metrics on sarcopenia rate in gastric cancer patients treated with adjuvant chemoradiotherapy. Clin Nutr 2019;38:1713-20. [PMID: 30122263 DOI: 10.1016/j.clnu.2018.07.035] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
657 Korn WM. Prevention and management of early esophageal cancer. Curr Treat Options Oncol. 2004;5:405-416. [PMID: 15341678 DOI: 10.1007/s11864-004-0030-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
658 Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS. Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res 2009;2:317-23. [PMID: 27990200 DOI: 10.4021/gr2009.11.1322] [Reference Citation Analysis]
659 Hsieh CH, Liu CY, Hsieh YJ, Tai HC, Wang LY, Tsai TH, Chen YJ. Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil. PLoS One 2011;6:e21000. [PMID: 21695264 DOI: 10.1371/journal.pone.0021000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
660 Aoyama T, Yoshikawa T, Maezawa Y, Kano K, Numata M, Hara K, Komori K, Yamada T, Hayashi T, Sato T, Tamagawa H, Yukawa N, Rino Y, Masuda M, Ogata T, Cho H, Oshima T. The postoperative lean body mass loss at one month leads to a poor survival in patients with locally advanced gastric cancer. J Cancer 2019;10:2450-6. [PMID: 31258750 DOI: 10.7150/jca.30697] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
661 Lorenzon L, Giudicissi R, Scatizzi M, Balducci G, Cantafio S, Biondi A, Persiani R, Mercantini P, D'Ugo D. D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature. BMC Surg 2020;20:126. [PMID: 32522177 DOI: 10.1186/s12893-020-00714-x] [Reference Citation Analysis]
662 Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, Quiroga AG, Perona R, Sanchez-Perez I. XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells. Front Pharmacol 2018;9:1197. [PMID: 30386247 DOI: 10.3389/fphar.2018.01197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
663 Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, Chang JC. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med 2012;4:291-6. [PMID: 23139717 DOI: 10.3892/etm.2012.591] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
664 Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 2018;21:1004-13. [PMID: 29730720 DOI: 10.1007/s10120-018-0832-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
665 Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One. 2012;7:e40364. [PMID: 22808142 DOI: 10.1371/journal.pone.0040364] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
666 Hwang JE, Ki MS, Kim K, Jung SH, Shim HJ, Bae WK, Hwang EC, Hur YH, Jeong O, Ryu SY, Park YK, Cho SH, Lee JS, Chung IJ. The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. Oncotarget 2017;8:66559-68. [PMID: 29029536 DOI: 10.18632/oncotarget.16301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
667 Yu JI, Park HC, Lee J, Choi C, Kang WK, Park SH, Kim ST, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim KM, Han H, Kim K, Kim S, Lim DH. Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. Cancers (Basel) 2020;12:E943. [PMID: 32290335 DOI: 10.3390/cancers12040943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
668 Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med 2020;9:E3495. [PMID: 33138060 DOI: 10.3390/jcm9113495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
669 Matsuo T, Nishizuka SS, Ishida K, Endo F, Katagiri H, Kume K, Ikeda M, Koeda K, Wakabayashi G. Evaluation of chemosensitivity prediction using quantitative dose-response curve classification for highly advanced/relapsed gastric cancer. World J Surg Oncol 2013;11:11. [PMID: 23339659 DOI: 10.1186/1477-7819-11-11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
670 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
671 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-490. [PMID: 19625077 DOI: 10.1016/s0140-6736(09)] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
672 Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
673 Clemente-Gutiérrez U, Rodríguez-Chong JG, Morales-Maza J, Rodríguez-Quintero JH, Sánchez-Morales G, Álvarez-Bautista FE, Cortés R, Medina-Franco H. Contrast-enhanced swallow study sensitivity for detecting esophagojejunostomy leakage. Rev Gastroenterol Mex (Engl Ed) 2020;85:118-22. [PMID: 31257112 DOI: 10.1016/j.rgmx.2019.02.013] [Reference Citation Analysis]
674 Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol 2015;36:219-28. [PMID: 26811591 DOI: 10.4103/0971-5851.171542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
675 Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.Oncotarget. 2016;44608. [DOI: 10.18632/oncotarget.10115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
676 Domen H, Ohara M, Noguchi M, Nakanishi Y, Komuro K, Iwashiro N, Ishizaka M. Long-term survival of resected advanced gastric cancer with hepatic and pancreatic invasion. Case Rep Gastroenterol 2011;5:396-403. [PMID: 21792349 DOI: 10.1159/000330374] [Reference Citation Analysis]
677 Li Z, Zeng J, Wang Z, Zhu H, Wei Y. Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer. Oncol Lett 2014;8:1427-34. [PMID: 25202345 DOI: 10.3892/ol.2014.2363] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
678 Yang L, Yang Y, Qin Q, Zhou A, Zhao J, Wang J, Shu C, Yuan X, Hu S. Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer. Mol Clin Oncol 2014;2:93-8. [PMID: 24649314 DOI: 10.3892/mco.2013.191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
679 Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 2009;126:615-628. [PMID: 19657673 DOI: 10.1007/s00439-009-0722-x] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 11.2] [Reference Citation Analysis]
680 Geng W, Tian D, Wang Q, Shan S, Zhou J, Xu W, Shan H. DNA‑PKcs inhibitor increases the sensitivity of gastric cancer cells to radiotherapy. Oncol Rep 2019;42:561-70. [PMID: 31173270 DOI: 10.3892/or.2019.7187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
681 Nakauchi M, Vos E, Janjigian YY, Ku GY, Schattner MA, Nishimura M, Gonen M, Coit DG, Strong VE. Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Ann Surg Oncol 2021;28:3532-44. [PMID: 33709174 DOI: 10.1245/s10434-021-09798-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
682 Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol. 2013;5:143-151. [PMID: 23450234 DOI: 10.1177/1758834012469429] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
683 Sun Y, Yu W, Guan W, Cai L, Qiao M, Zheng L, Jiang R, Wang R, Wang L. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag Res 2019;11:6397-410. [PMID: 31372044 DOI: 10.2147/CMAR.S206189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
684 Yang Y, Ma Y, Xiang X, Xing P, Wu Y, Zhang L, Tian Y. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China. Radiat Oncol 2020;15:237. [PMID: 33054848 DOI: 10.1186/s13014-020-01687-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
685 Duan S, Wang P, Liu F, Huang H, An W, Pan S, Wang X. Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med 2019;8:2675-85. [PMID: 30945466 DOI: 10.1002/cam4.2077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
686 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573 [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
687 Schuhmacher C, Novotny A, Meyer HJ. [Treatment of gastric cancer beyond current guideline: state of the art]. Chirurg 2013;84:310-5. [PMID: 23479274 DOI: 10.1007/s00104-012-2454-z] [Reference Citation Analysis]
688 Wang M, Chen L, Chen Y, Wei R, Guo Q, Zhu S, Guo S, Zhu S, Zhang S, Min L. Intracellular matrix Gla protein promotes tumor progression by activating JAK2/STAT5 signaling in gastric cancer. Mol Oncol 2020;14:1045-58. [PMID: 32086862 DOI: 10.1002/1878-0261.12652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
689 Nassour I, Fullington H, Hynan LS, Yopp AC, Augustine MM, Polanco PM, Choti MA, Mansour JC, Wang SC, Porembka MR. The Yield of Staging Laparoscopy in Gastric Cancer is Affected by Racial and Ethnic Differences in Disease Presentation. Ann Surg Oncol 2017;24:1787-94. [PMID: 28194592 DOI: 10.1245/s10434-017-5805-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
690 Socha J, Wołąkiewicz G, Wasilewska-Teśluk E, Janiga P, Kondraciuk T, Majewska A, Olearski K, Kępka L. Clinical target volume in postoperative radiotherapy for gastric cancer: identification of major difficulties and controversies. Clin Transl Oncol 2016;18:480-8. [PMID: 26311079 DOI: 10.1007/s12094-015-1396-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
691 Anderson E, LeVee A, Kim S, Atkins K, Guan M, Placencio-Hickok V, Moshayedi N, Hendifar A, Osipov A, Gangi A, Burch M, Waters K, Cho M, Klempner S, Chao J, Kamrava M, Gong J. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. JAMA Netw Open 2021;4:e2138432. [PMID: 34889947 DOI: 10.1001/jamanetworkopen.2021.38432] [Reference Citation Analysis]
692 Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28 Suppl 1:S152-61. [PMID: 20730572 DOI: 10.1007/s12032-010-9658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
693 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
694 Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, Mariette C. Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg. 2012;36:346-354. [PMID: 22102091 DOI: 10.1007/s00268-011-1351-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
695 Wang P, Zhou H, Han G, Ni Q, Dai S, Huang J, Dai C, Yu L. Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression. World J Surg Oncol 2021;19:205. [PMID: 34238296 DOI: 10.1186/s12957-021-02304-4] [Reference Citation Analysis]
696 Fuse N, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer. 2017;20:332-340. [PMID: 26956689 DOI: 10.1007/s10120-016-0606-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
697 Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, Montgomery E, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg. 2005;9:718-725. [PMID: 15862270 DOI: 10.1016/j.gassur.2004.12.002] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 5.5] [Reference Citation Analysis]
698 Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res 2013;19:2646-56. [PMID: 23669424 DOI: 10.1158/1078-0432.CCR-12-2939] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
699